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Summary of findings {#CD005436-sec-0023}
===================

###### \'Summary of findings\' table 1

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------- -------------------------------------- ---------------------------------------- ------------------------- ------------
  **Zinc compared to placebo for children more than 6 months of age with acute diarrhoea**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Patient or population:** children with acute diarrhoea  **Settings:** all countries  **Intervention:** zinc  **Comparison:** placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**                                   **Relative effect  (95% CI)**           **Number of participants  (trials)**   **Certainty of the evidence  (GRADE)**   **Comments**              

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                                                                                            

  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Zinc**                                                                                                                                                                                                                          

  **Duration of diarrhoea**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **All trials**                                                                  **MD** −**11.46**   (−19.72 to −3.19)   2581  (9 trials)                       ⊕⊕⊝⊝  **low**^1,2^                       No comment                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  The mean duration of diarrhoea among placebo ranged from **31.2 to 169.5 hours**                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The mean duration of diarrhoea among zinc ranged from **28.8 to 147.6 hours**                                                                                                                                                     

  **Trials limited to children with signs of malnutrition**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **MD** −**26.39**   (−36.54 to −16.23)                                          419  (5 trials)                         ⊕⊕⊕⊕\                                  No comment                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **high**                                                                                                  

  The mean duration of diarrhoea among placebo ranged from **103.4 to 146.4 hours**                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The mean duration of diarrhoea among zinc ranged from **70.4 to 120.0 hours**                                                                                                                                                     

  **Diarrhoea on day 7**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **128 per 1000**                                                                **93 per 1000**   (78 to 113)           **RR 0.73**\                           3865  (6 trials)                         ⊕⊕⊕⊝\                     No comment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (0.61 to 0.88)                                                                  **moderate**^3^           

  **Number of children hospitalized**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ---                                                                             ---                                     ---                                    276  (1 trial)                           ⊕⊝⊝⊝  **very low**^4,5^   No events
  (community trials only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  **Death**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **5 per 1000**                                                                  **1 per 1000**   (0 to 11)              **RR 0.29**\                           1134  (4 trials)                         ⊕⊝⊝⊝  **very low**^6,7^   Few events
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (0.04 to 2.20)                                                                                            

  **Adverse events (vomiting)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **119 per 1000**                                                                **188 per 1000**   (173 to 242)         **RR 1.57**\                           2605  (6 trials)                         ⊕⊕⊕⊝\                     No comment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (1.32 to 1.86)                                                                  **moderate**^8^           

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  Abbreviations: **CI:** confidence interval; **MD:** mean difference; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                                                             

  GRADE Working Group grades of evidence  **High certainty:** further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** we are very uncertain about the estimate.                                                                                                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------- -------------------------------------- ---------------------------------------- ------------------------- ------------

^1^Downgraded by 1 for indirectness: all trials were conducted in Asia.  ^2^Downgraded by 1 for serious imprecision: wide CI.  ^3^Downgraded by 1 for serious indirectness: these trials were all conducted in Asia in countries at high risk of zinc deficiency.  ^4^Downgraded by 1 for serious indirectness: only one small community trial reported on number of children hospitalized.  ^5^Downgraded by 2 for very serious imprecision: no hospitalizations occurred in this trial.  ^6^Downgraded by 1 for serious indirectness: the included trials were mostly conducted in hospitals and are therefore likely to underestimate death at the community level.  ^7^Downgraded by 2 for very serious imprecision: only three deaths occurred in these two trials, consequently the trials are significantly underpowered to detect or exclude an effect.  ^8^Downgraded by 1 for serious risk of bias: two trials reported no details on sequence generation, allocation concealment, blinding, and incomplete outcome data, while one did not give any details regarding allocation concealment.

###### \'Summary of findings\' table 2

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------- ---------------------------------------- ------------------------- --------------------------------------
  **Zinc compared to placebo for children aged less than 6 months with acute diarrhoea**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Patient or population:** children aged less than 6 months with acute diarrhoea  **Settings:** all countries  **Intervention:** zinc  **Comparison:** placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**                                      **Relative effect  (95% CI)**                                                    **Number of participants  (trials)**   **Certainty of the evidence  (GRADE)**   **Comments**              

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                                                                                                                                        

  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Zinc**                                                                                                                                                                                                                                                                      

  **Duration of diarrhoea**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The mean duration of diarrhoea among placebo ranged from **97.9 to 133.2 hours**   The mean duration of diarrhoea among zinc ranged from **105.6 to 133.2 hours**   **MD 5.23**   (−4.00 to 14.45)         1334  (2 trials)                         ⊕⊕⊝⊝  **low**^1,2^        No comment

  **Diarrhoea on day 7**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **203 per 1000**                                                                   **252 per 1000**   (201 to 313)                                                  **RR 1.24**   (0.99 to 1.54)           1074  (1 trial)                          ⊕⊕⊝⊝\                     No comment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **low**^3,4^              

  **Number of children hospitalized** (community trials only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ---                                                                                ---                                                                              ---                                    1074  (1 trial)                          ⊕⊝⊝⊝  **very low**^5,6^   No events

  **Death**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **2 per 1000**                                                                     **2 per 1000**\                                                                  **RR 1.00**\                           1334  (2 trials)                         ⊕⊝⊝⊝  **very low**^7,8^   Only 1 event in each treatment group
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (0 to 32)                                                                        (0.06 to 15.89)                                                                                           

  **Adverse events (vomiting)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **64 per 1000**                                                                    **104 per 1000**   (67 to 143)                                                   **RR 1.54**   (1.05 to 2.24)           1334  (2 trials)                         ⊕⊕⊕⊝\                     No comment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **moderate**^9^           

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  Abbreviations: **CI:** confidence interval; **MD:** mean difference; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                         

  GRADE Working Group grades of evidence  **High certainty:** further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** we are very uncertain about the estimate.                                                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------- ---------------------------------------- ------------------------- --------------------------------------

^1^Downgraded by 1 for inconsistency: only two trials were done and both had inconsistent results.  ^2^Downgraded by 1 for imprecision: large CI.  ^3^Downgraded by 1 for inconsistency: different results in the subgroups.  ^4^Downgraded by 1 for indirectness: only one trial (although multi‐country) as it is not possible to generalize these results.  ^5^Downgraded by 2 for imprecision: only one hospitalization was recorded in 1074 participants. Much larger trials would be necessary to prove or exclude an effect.  ^6^Downgraded by 1 for imprecision: the result is not statistically significant.  ^7^Downgraded by 1 for indirectness: most of this data is from Asia and may not be applicable elsewhere.  ^8^Downgraded by 2 for imprecision: in these two trials deaths were very rare, and consequently these trials are significantly underpowered to detect or exclude an effect on mortality.  ^9^Downgraded by 1 under consistency because only two trials were done.

###### \'Summary of findings\' table 3

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------- -------------------------------------- ---------------------------------------- ------------------------- ------------
  **Zinc compared to placebo for children with persistent diarrhoea**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Patient or population:** children with persistent diarrhoea  **Settings:** all countries  **Intervention:** zinc  **Comparison:** placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**                            **Relative effect  (95% CI)**                                                   **Number of participants  (trials)**   **Certainty of the evidence  (GRADE)**   **Comments**              

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                                                                                                                             

  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Zinc**                                                                                                                                                                                                                                                           

  **Duration of diarrhoea**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The mean duration of diarrhoea among placebo ranged from **84 to 132**   The mean duration of diarrhoea among zinc ranged from **69.4 to 122.4 hours**   **MD −15.84**   (−25.43 to −6.24)      529  (5 trials)                          ⊕⊕⊕⊝  **moderate**^1^     No comment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Diarrhoea on day 7**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **191 per 1000**                                                         **99 per 1000**   (52 to 195)                                                   **RR 0.52**   (0.27 to 1.02)           221  (2 trials)                          ⊕⊕⊝⊝  **low**^1,2^        No comment

  **Hospitalization**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ---                                                                      ---                                                                             ---                                    275  (1 trial)                           ⊕⊝⊝⊝  **very low**^1,3^   No events

  **Death**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ---                                                                      ---                                                                             ---                                    402  (3 trials)                          ⊕⊝⊝⊝  **very low**^1,4^   No events

  **Adverse events (vomiting)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **8 per 1000**                                                           **16 per 1000**   (3 to 85)                                                     **RR 1.97**   (0.37 to 10.59)          505  (4 trials)                          ⊕⊝⊝⊝  **very low**^1,5^   No comment

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **Abbreviations: CI:** confidence interval; **MD:** mean difference; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                              

  GRADE Working Group grades of evidence  **High certainty:** further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** we are very uncertain about the estimate.                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------- -------------------------------------- ---------------------------------------- ------------------------- ------------

^1^Downgraded by 1 for indirectness: most of this data is from Asia and may not be applicable elsewhere.  ^2^Downgraded by 1 for imprecision: the result does not reach statistically significance, and the number of recorded events is low.  ^3^Downgraded by 2 for imprecision: no hospitalizations were recorded. Much larger trials would be necessary to prove or exclude an effect.  ^4^Downgraded by 2 for imprecision: in these three trials deaths were very rare, and consequently these trials are significantly underpowered to detect or exclude an effect on mortality.  ^5^Downgraded by 2 for imprecision: vomiting was very uncommon in these trials.

Background {#CD005436-sec-0024}
==========

Description of the condition {#CD005436-sec-0025}
----------------------------

Despite improving trends in mortality rates, diarrhoea still causes nearly 10% of all deaths in children under five years of age and accounts for about 500,000 child deaths in developing countries every year ([Liu 2015a](#CD005436-bbs2-0210){ref-type="ref-list"}; [Liu 2015b](#CD005436-bbs2-0211){ref-type="ref-list"}). The incidence of diarrhoea decreased from 3.4 episodes per child‐year in 1990 to 2.9 episodes per child‐year in 2010. However, it still remains one of the most common reasons of hospital admission, with an estimated 1731 million episodes of childhood diarrhoea reported in 2011 of which 2% progressed to severe disease ([Das 2014](#CD005436-bbs2-0191){ref-type="ref-list"}). Diarrhoea is also an important cause of malnutrition, particularly when it is prolonged ([Brown 2003](#CD005436-bbs2-0190){ref-type="ref-list"}).

Zinc deficiency is mainly due to inadequate dietary intake and is estimated to be common in many countries, especially in children ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}; [Wagstaff 2004](#CD005436-bbs2-0221){ref-type="ref-list"}; [Hess 2009](#CD005436-bbs2-0199){ref-type="ref-list"}). According to recent estimates, 17.3% of the world's population is currently at risk of inadequate zinc intake ([Wessells 2012](#CD005436-bbs2-0222){ref-type="ref-list"}). The regional estimated prevalence of inadequate zinc intake ranges from 7.5% in high‐income regions to 30% in South Asia ([Wessells 2012](#CD005436-bbs2-0222){ref-type="ref-list"}). Foods more rich in zinc are \'expensive foods\', such as meat and fish ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Zinc is also present in nuts, seeds, legumes, and wholegrain cereal, but the high phytate content of these foods interferes with its absorption ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Zinc cannot be stored in the body, and nearly 50% of zinc excretion takes place through the gastrointestinal tract and is increased during episodes of diarrhoea ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Zinc requirement varies with age and is highest in children due to their rapid rates of growth. As a consequence, young children who are regularly exposed to gastrointestinal pathogens and have diets low in animal products and high in phytate‐rich foods are most at risk of zinc deficiency ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}).

Description of the intervention {#CD005436-sec-0026}
-------------------------------

Treatment of diarrhoea with oral rehydration solution (ORS) reduces mortality due to dehydration ([Liu 2015a](#CD005436-bbs2-0210){ref-type="ref-list"}; [Liu 2015b](#CD005436-bbs2-0211){ref-type="ref-list"}). In addition to ORS, the World Health Organization (WHO) and United Nations Children\'s Fund (UNICEF) recommend for children under five years of age with diarrhoea a supplementation with 10 to 20 mg of zinc per day, at least twice the recommended daily allowance ([WHO/UNICEF 2004](#CD005436-bbs2-0223){ref-type="ref-list"}). Zinc is usually given as zinc sulphate, zinc acetate, or zinc gluconate, which are all water‐soluble compounds ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}).

How the intervention might work {#CD005436-sec-0027}
-------------------------------

There are several different mechanism of action of zinc on acute diarrhoea ([Berni Canani 2010](#CD005436-bbs2-0187){ref-type="ref-list"}; [Krebs 2014](#CD005436-bbs2-0207){ref-type="ref-list"}). Zinc influences the activity of over 300 enzymes, some of which are responsible for DNA replication and transcription ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Zinc promotes immunity, skin and mucosal resistance to infection, growth, and development of the nervous system ([MacDonald 2000](#CD005436-bbs2-0213){ref-type="ref-list"}; [Prasad 2008](#CD005436-bbs2-0217){ref-type="ref-list"}; [Hess 2009](#CD005436-bbs2-0199){ref-type="ref-list"}). It is also an important antioxidant and preserves cellular membrane integrity ([O\'Dell 2000](#CD005436-bbs2-0214){ref-type="ref-list"}; [Powell 2000](#CD005436-bbs2-0216){ref-type="ref-list"}; [Prasad 2014](#CD005436-bbs2-0218){ref-type="ref-list"}). At the level of gastrointestinal system, zinc restores mucosal barrier integrity and enterocyte brush‐border enzyme activity ([Roy 1992](#CD005436-bbs2-0150){ref-type="ref-list"}; [Shankar 1998](#CD005436-bbs2-0165){ref-type="ref-list"}), it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens ([Sazawal 1997b](#CD005436-bbs2-0220){ref-type="ref-list"}; [Albert 2003](#CD005436-bbs2-0186){ref-type="ref-list"}; [Raqib 2004](#CD005436-bbs2-0144){ref-type="ref-list"}), and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3‐5‐cyclic monophosphate‐mediated chlorine secretion ([Hoque 2005](#CD005436-bbs2-0201){ref-type="ref-list"}; [Hoque 2009](#CD005436-bbs2-0202){ref-type="ref-list"}).

Zinc supplementation may have different effects according to the level of zinc deficiency in the country and in the individual. It is important to verify whether zinc supplementation is effective in countries with high, or even medium or low risk of zinc deficiency ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Despite an accurate estimation of the prevalence of zinc deficiency in populations is hampered by the lack of reliable indicators or biomarkers ([Wieringa 2015](#CD005436-bbs2-0224){ref-type="ref-list"}), indirect indicators such as the prevalence of stunting or anaemia, and the absorbable zinc content of the national food supply are currently used at to estimate the prevalence of zinc deficiency in populations ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Zinc requirements are higher in malnourished children because nutritional zinc deficiency is considered more severe in these children ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). However, infants have lower requirements ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}), as healthy normal birthweight infants have adequate zinc levels at birth from maternal sources even if maternal stores are suboptimal ([Iqbal 2001](#CD005436-bbs2-0203){ref-type="ref-list"}). Infants may also be able to mobilize hepatic stores accumulated during gestation ([Zlotkin 1988](#CD005436-bbs2-0225){ref-type="ref-list"}), and are less likely to have had a zinc‐depleting illness. Breastfeeding will provide zinc supplementation and protective immune factors against infections ([Krebs 1999](#CD005436-bbs2-0206){ref-type="ref-list"}).

Zinc can cause vomiting because of its metallic taste ([Fontaine 2001](#CD005436-bbs2-0194){ref-type="ref-list"}). In high doses, zinc can also cause epigastric pain, lethargy, and fatigue ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). One small study suggested a possible increase in mortality in malnourished children supplemented with 6 mg/kg/day of zinc compared to those supplemented with 1.5 mg/kg/day ([Doherty 1998](#CD005436-bbs2-0082){ref-type="ref-list"}). Copper deficiency with zinc supplementation can occur although usually only when zinc is consumed in very high doses (100 to 300 mg/day for adults) over a long period of time ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}), and malnourished children are at particularly high risk of this due to lower basal copper levels.

Iron and zinc deficiencies often co‐exist. These two compounds may compete for the same absorptive pathways, and iron may interfere with zinc utilization ([Gunshin 1997](#CD005436-bbs2-0197){ref-type="ref-list"}; [Kordas 2004](#CD005436-bbs2-0205){ref-type="ref-list"}). A review of combined supplementation showed that giving zinc with iron resulted in a lower increase in iron levels compared to giving iron alone; iron supplementation alone had no effect on zinc status ([Fischer Walker 2005](#CD005436-bbs2-0193){ref-type="ref-list"}). A trial that assessed combined supplementation on diarrhoea and malaria morbidity showed that zinc combined with iron reduced zinc\'s protective effect against diarrhoea ([Richard 2006](#CD005436-bbs2-0145){ref-type="ref-list"}). Several trials have also reported a negative interaction of the combined supplementation on physical growth and development ([Rosado 1997](#CD005436-bbs2-0147){ref-type="ref-list"}; [Dijkhuizen 2001](#CD005436-bbs2-0192){ref-type="ref-list"}; [Zlotkin 2003](#CD005436-bbs2-0226){ref-type="ref-list"}; [Lind 2004](#CD005436-bbs2-0110){ref-type="ref-list"}; [Bhandari 2007](#CD005436-bbs2-0059){ref-type="ref-list"}). Some protocols suggest supplementing malnourished children also with copper because these children are also prone to copper deficiency ([Beshgetoor 1998](#CD005436-bbs2-0188){ref-type="ref-list"}).

Why it is important to do this review {#CD005436-sec-0028}
-------------------------------------

Previous meta‐analysis and systematic reviews have indicated that zinc supplementation in diarrhoea is effective ([Bhutta 2000b](#CD005436-bbs2-0189){ref-type="ref-list"}; [Lukacik 2008](#CD005436-bbs2-0212){ref-type="ref-list"}; [Patro 2008](#CD005436-bbs2-0215){ref-type="ref-list"}; [Haider 2009](#CD005436-bbs2-0198){ref-type="ref-list"}; [Liberato 2015](#CD005436-bbs2-0209){ref-type="ref-list"}; [Zou 2015](#CD005436-bbs2-0227){ref-type="ref-list"}; [Lazzerini 2016](#CD005436-bbs2-0208){ref-type="ref-list"}). This Cochrane Review will have an up‐to‐date extensive search for trials, will explore more outcome measures of interest, and will report on more possible sources of heterogeneity. This Cochrane Review updates the last published version of this review ([Lazzerini 2013](#CD005436-bbs2-0231){ref-type="ref-list"}).

Objectives {#CD005436-sec-0029}
==========

To evaluate oral zinc supplementation for treating children with acute or persistent diarrhoea.

Methods {#CD005436-sec-0030}
=======

Criteria for considering studies for this review {#CD005436-sec-0031}
------------------------------------------------

### Types of studies {#CD005436-sec-0032}

Randomized controlled trials (RCTs).

### Types of participants {#CD005436-sec-0033}

Children between one month and five years of age with acute or persistent diarrhoea, including dysentery.

We excluded trials of infants below one month of age and studies that exclusively enrolled children with particular conditions, such preterm or low birthweight infants and children with HIV.

Acute diarrhoea is usually defined as three or more loose stools in a 24‐hour period. Persistent diarrhoea is defined as diarrhoea lasting more than 14 days. Dysentery is a diarrhoeal illness in which blood is observed in the stool. The final day of diarrhoea is usually defined as the last day meeting the above definition followed by 48 hours without diarrhoea.

### Types of interventions {#CD005436-sec-0034}

#### Intervention {#CD005436-sec-0035}

Oral zinc supplementation of any zinc salt at doses of 5 mg/day or more for any duration.

#### Control {#CD005436-sec-0036}

Placebo.

Concurrent supplementation of other minerals and vitamins are eligible only if administered to both the intervention and control groups.

We excluded ORS plus zinc and food fortification interventions (such as milk fortification) as the amount of ORS/food consumed, and hence the zinc intake, would be less certain.

### Types of outcome measures {#CD005436-sec-0037}

#### Primary outcomes {#CD005436-sec-0038}

##### Measures of diarrhoea duration {#CD005436-sec-0039}

Diarrhoea duration.Diarrhoea at 3, 5, and 7 days after starting the intervention.

##### Measures of diarrhoea severity {#CD005436-sec-0040}

Stool frequency.Stool output.

#### Secondary outcomes {#CD005436-sec-0041}

Hospitalization (number of children hospitalized).Death (from any cause and diarrhoea specific).

##### Adverse events {#CD005436-sec-0042}

Serious adverse events (life‐threatening or requiring hospitalization).Any adverse event that results in the discontinuation of treatment.Other adverse events, such as vomiting and reduced copper levels.

Search methods for identification of studies {#CD005436-sec-0043}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD005436-sec-0044}

We searched the following databases using the search terms and strategy described in [Table 4](#CD005436-tbl-0004){ref-type="table"}: the Cochrane Infectious Diseases Group Specialized Register (30 September 2016); Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2016, Issue 9); MEDLINE (1966 to 30 September 2016); Embase (1974 to 30 September 2016); LILACS (1982 to 30 September 2016); CINAHL (1982 to 30 September 2016), the *meta*Register of Current Controlled Trials (*m*RCT; 30 September 2016), ClinicalTrials.gov (30 September 2016), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (30 September 2016).

###### Detailed search strategies

  ---------------- ----------------- ----------------- ----------------------- ------------------ ----------------- ----------------- -----------------
  **Search set**   **CIDG SR^1^**    **CENTRAL**       **MEDLINE^2^**          **EMBASE^2^**      **LILACS^2^**     **CINAHL**        **CCT**
  1                zinc              zinc              zinc                    zinc               zinc              zinc              zinc
  2                diarrhoea         diarrhoea         ZINC                    ZINC               diarrhoea         diarrhoea         diarrhoea
  3                vomiting          morbidity         1 or 2                  1 or 2             morbidity         morbidity         vomiting
  4                adverse effects   2 or 3            diarrhoea               diarrhoea          2 or 3            2 or 3            adverse effects
  5                ---               1 and 4           diarrhoea               morbidity          1 and 4           1 and 4           ---
  6                ---               vomiting          morbidity               4 or 5             vomiting          vomiting          ---
  7                ---               adverse effects   MORBIDITY               3 and 6            adverse effects   adverse effects   ---
  8                ---               6 or 7            4 or 5 or 6 or 7        Limit 7 to human   6 or 7            6 or 7            ---
  9                ---               1 and 2 and 8     3 and 8                 vomiting           1 and 2 and 8     1 and 8           ---
  10               ---               ---               Limit 9 to human        adverse effects    ---               ---               ---
  11               ---               ---               vomiting                9 or 10            ---               ---               ---
  12               ---               ---               adverse effects         3 and 4 and 11     ---               ---               ---
  13               ---               ---               11 or 12                ---                ---               ---               ---
  14               ---               ---               3 and (4 or 5) and 13   ---                ---               ---               ---
  ---------------- ----------------- ----------------- ----------------------- ------------------ ----------------- ----------------- -----------------

^1^Cochrane Infectious Diseases Group Specialized Register.  ^2^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane (Higgins 2006); upper case: MeSH or EMTREE heading; lower case: free text term.

### Searching other resources {#CD005436-sec-0045}

#### Researchers and organizations {#CD005436-sec-0046}

For unpublished and ongoing trials, we contacted individual researchers working in the field, including researchers at the WHO.

#### Reference lists {#CD005436-sec-0047}

We checked the reference lists of all studies identified by the above methods.

Data collection and analysis {#CD005436-sec-0048}
----------------------------

### Selection of studies {#CD005436-sec-0049}

Both review authors screened all trials identified by the search strategy by title/abstract, and we retrieved the full‐text articles of all potentially relevant trials. Both review authors independently applied the inclusion criteria to the full‐text reports using a pilot‐tested data extraction form, and scrutinized publications to ensure we included each trial only once. We contacted the trial authors for clarification if necessary, and resolved any disagreements through discussion and consensus after referring to the protocol; we recorded and reported their solutions. We listed studies excluded after full‐text assessment and their reasons for exclusion in a \'[Characteristics of excluded studies](#CD005436-sec-0134){ref-type="sec"}\' table. We constructed a PRISMA flow diagram to illustrate the study selection process.

### Data extraction and management {#CD005436-sec-0050}

Both review authors independently extracted data using a pilot‐tested data extraction form and entered the data into Review Manager 5 (RevMan 5) ([Review Manager 5](#CD005436-bbs2-0219){ref-type="ref-list"}). When data were missing or unclear, we contacted the trial authors for clarification. For dichotomous outcomes, we recorded the number of participants that experienced the event and the number of participants assessed in each group. For continuous outcomes, we extracted the arithmetic mean values, standard deviation (SD) values, and the number of participants assessed in each group. If a trial reported continuous data using geometric means, we extracted the SD values on the log scale; we extracted median and range values and reported these in a table.

### Assessment of risk of bias in included studies {#CD005436-sec-0051}

Both review authors independently assessed the risk of bias for each trial using the Cochrane \'Risk of bias\' assessment tool ([Higgins 2011](#CD005436-bbs2-0200){ref-type="ref-list"}). We categorized our judgments as either at low, high, or unclear risk of bias, and we used this information to guide our interpretation of the results. Where the judgement for efficacy trials was \'unclear\' we attempted to contact the trial authors for clarification and we resolved any differences of opinion through discussion. If data were missing or unclear, we contacted the trial authors for further information.

### Measures of treatment effect {#CD005436-sec-0052}

For dichotomous data, we reported outcome measures using the risk ratio (RR). For continuous data summarized by arithmetic means and SDs, we used the mean difference (MD) values to combine the results in a meta‐analysis. We presented continuous data summarized using other summary statistics that we could not combine in a meta‐analysis in a table. We calculated the geometric mean ratios and transformed them in the log scale for analysis, and presented them on the natural scale

### Unit of analysis issues {#CD005436-sec-0053}

There were no cluster RCTs.

### Dealing with missing data {#CD005436-sec-0054}

We planned to conduct an analysis so that we included all individuals with a recorded outcome in the analysis. If there was missing information or we needed more details on reported measures, we sought further clarification from the trial authors. To take into account the participants for whom there was no outcome data available, we also conducted an intention‐to‐treat (ITT) analysis for worst‐case/best‐case scenarios.

### Assessment of heterogeneity {#CD005436-sec-0055}

We assessed heterogeneity between trials by visually inspecting the forest plot, using the Chi² test for heterogeneity with a 5% level of statistical significance, and the I² statistic with a value of 50% representing a moderate level of heterogeneity. If we detected significant heterogeneity but considered it was appropriate to pool data, we used the random‐effects model.

### Assessment of reporting biases {#CD005436-sec-0056}

We constructed funnel plots to look for evidence of publication bias for the outcome duration of diarrhoea and diarrhoea at day 7.

### Data synthesis {#CD005436-sec-0057}

We analysed the data using RevMan 5 ([Review Manager 5](#CD005436-bbs2-0219){ref-type="ref-list"}). We presented all results with 95% confidence intervals (CIs).

#### Quality of the evidence {#CD005436-sec-0058}

We assessed the certainty of the evidence using the GRADE approach ([GRADEpro GDT 2014](#CD005436-bbs2-0196){ref-type="ref-list"}). We used GRADEpro Guideline Development Tool (GDT) software to construct the \'Summary of findings\' tables ([GRADEpro GDT 2014](#CD005436-bbs2-0196){ref-type="ref-list"}). The GRADE system considers 'certainty' to be a judgment of the extent to which we can be confident that the estimates of effect are correct. The level of 'certainty' is judged on a four‐point scale. Evidence from RCTs is initially graded as high and downgraded by either 1, 2, or 3 levels after full consideration of: any limitations in the design of the studies, the directness (or applicability) of the evidence, the consistency and precision of the results, and the possibility of publication bias.

We have displayed the estimates of effect, and the GRADE assessments of our confidence in these estimates in \'Summary of findings tables\' for the main comparisons. Where we have downgraded the evidence our reasons for doing so are displayed in footnotes.

When making conclusions about the relative effects of the interventions we used language that reflected the GRADE assessments and our confidence in the estimates, that is if the evidence was of high certainty we said \"zinc reduces\"; if it was of moderate certainty we stated \"zinc probably reduces\"; it was of low certainty we used \"zinc may reduce\"; and where the evidence was of very low certainty we did not draw conclusions.

### Subgroup analysis and investigation of heterogeneity {#CD005436-sec-0059}

We stratified the analyses for acute diarrhoea or persistent diarrhoea as these are different conditions. We also stratified the results by age (children aged less than and greater than six months) because we observed a clear difference in zinc effect according to the age of children enrolled and significant heterogeneity if we pooled all the trials together. We explored the following potential sources of heterogeneity using subgroup analyses: nutritional status (malnourished children versus well‐nourished plus moderate malnourished); geographical region (by continent and by high versus medium estimated risk of zinc deficiency as defined by the International Zinc Nutrition Consultative Group (IZiNCG) ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"})); zinc dose (less than versus greater than 20 mg/day); zinc salt (zinc sulphate versus zinc acetate versus zinc gluconate versus other type); concomitant copper or iron supplementation; and trial setting (hospital versus community trials). We also explored the effect of sex, although we did not specify this in the original Cochrane Protocol ([Lazzerini 2005](#CD005436-bbs2-0228){ref-type="ref-list"}).

### Sensitivity analysis {#CD005436-sec-0060}

We conducted a sensitivity analysis in which we limited the analyses to those trials with adequate allocation concealment, blinding (excluded those trials classified as unclear), and those that included an adequate number of randomized participants in the analysis (excluded those trials classified as inadequate or unclear). To take into account the participants for whom no outcome data were available, we also conducted an ITT analysis for worst‐case/best‐case scenarios.

Results {#CD005436-sec-0061}
=======

Description of studies {#CD005436-sec-0062}
----------------------

### Results of the search {#CD005436-sec-0063}

In the previous version of this review, [Lazzerini 2013](#CD005436-bbs2-0231){ref-type="ref-list"}, 24 trials met the inclusion criteria. We updated the literature search to 30 September 2016 and identified 68 records after removal of duplicates. After screening the articles by title and abstract, we excluded 48 articles and assessed 20 articles for eligibility. Nine new trials met the inclusion criteria of the review and thus we included 33 trials (10,841 children) in this review update. We have presented a PRISMA study flow diagram in [Figure 1](#CD005436-fig-0001){ref-type="fig"} and we have reported the trial selection process in [Table 5](#CD005436-tbl-0005){ref-type="table"}.

![Study flow diagram.](nCD005436-AFig-FIG01){#CD005436-fig-0001}

###### Results of the study selection

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------
  Total number of studies identified through the search (up to 30 September 2016)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  306 trials

  Total number of studies excluded as clearly did not concern the topic of interest                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                126 trials

  Studies further evaluated and excluded^1^\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       141 trials
  Not RCTs: 25 trialsNot placebo‐controlled RCTs: 8 trialsRCTs on prevention of diarrhoea, not on treatment: 51 trialsNot concerning the population of interest (for example, studies on low birthweight, HIV): 13 trialsNot concerning the interventions of interest (for example, studies on zinc in oral rehydration solution (ORS), multiple micronutrients, probiotics, food fortification): 19 trialsConcerning different outcomes (for example, studies on serology, appetite, mental or motor development, malnutrition): 16 trialsCould not be compared with other studies because of methodological problems (enrolling the same children more than once) and types of outcomes (episodes of diarrhoea and not children with diarrhoea): 1 trialSecondary analysis of other studies: 8   

  Duplicates of included studies\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  6 trials
  Folwaczny 1996; Darmon 1997 are review articles of the same trial ([Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"})Roy 1991 is a duplication of [Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"} and [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}[Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"} is an abstract of [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}Cuevas 2000 is an abstract of [Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}Patel 2013 is a cost effectiveness analysis based on data reported in [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}                                                                                                                                                                        

  Independent trials included in the review                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        33 trials (10,841 participants)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------

^1^See the \'[Characteristics of excluded studies](#CD005436-sec-0134){ref-type="sec"}\' section.  Abbreviations: HIV: human immunodeficiency virus; RCT: randomized controlled trial.

### Included studies {#CD005436-sec-0064}

Thirty‐three trials in total met the inclusion criteria of this review. We have listed the details of the included trials in the \'[Characteristics of included studies](#CD005436-sec-0133){ref-type="sec"}\' table. Three included trials presented results divided in two or more subgroups, and specifically: one trial presented two intervention groups of zinc 20 mg and zinc 5 mg, and one control group ([Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}); one trial presented data for three different study sites ([Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}); one trial presented the results as children with low and normal zinc serum levels ([Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}). For these three trials there was no way to combine mean values and standard deviation (SD) values, and thus we entered the data separately as [Brooks 2005a (20 mg)](#CD005436-bbs2-0007){ref-type="ref-list"}, [Brooks 2005a (5 mg)](#CD005436-bbs2-0008){ref-type="ref-list"}, [Fischer Walker 2006 ETH](#CD005436-bbs2-0016){ref-type="ref-list"}, [Fischer Walker 2006 IND](#CD005436-bbs2-0017){ref-type="ref-list"}, [Fischer Walker 2006 PAK](#CD005436-bbs2-0018){ref-type="ref-list"}, [Polat 2003 (low Zn)](#CD005436-bbs2-0032){ref-type="ref-list"}, and [Polat 2003 (normal Zn)](#CD005436-bbs2-0033){ref-type="ref-list"}.

#### Type of diarrhoea {#CD005436-sec-0065}

Most trials included children with acute diarrhoea only. Of these, 13 used the definition for acute diarrhoea that we used in this Cochrane Review ([Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}; [Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}; [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}; [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}; [Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}), two trials defined diarrhoea as the presence of either four ([Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}), or five ([Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}), unformed stools in 24 hours, one trial defined diarrhoea as acute onset of change in stool frequency and consistency ([Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}), one shigellosis trial included participants with bloody mucoid diarrhoea (dysentery) or febrile diarrhoea less than five days\' duration ([Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}).

Three trials enrolled only children with rotavirus infection ([Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}).

Eight trials did not report the definition of acute diarrhoea ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"};[Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}; [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}; [Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}).

Five trials were on children with persistent diarrhoea ([Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}).

#### Age {#CD005436-sec-0066}

Two trials only enrolled children under six months of age ([Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}). Seventeen trials only enrolled children over six months of age ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}; [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}; [Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}; [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}; [Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}; [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}; [Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}; [Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}). Fourteen trials included children of different ages greater than one month ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}; [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}; [Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}; [Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}; [Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}).

#### Nutritional status {#CD005436-sec-0067}

Eight trials only enrolled malnourished children ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}). Two trials included well‐nourished children ([Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}), and one trial enrolled children regardless of their nutritional status ([Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}), while the remaining 20 trials enrolled children who were well nourished or with mild or moderate malnutrition. No trials included only severe malnourished children. Two trials did not mention the nutritional status of children ([Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}). There was some variability between trials regarding the definition of malnutrition (most used \'weight/age\'; only some used \'weight/height\'); therefore we were unable to follow the definition of malnutrition proposed in our protocol ([Lazzerini 2005](#CD005436-bbs2-0228){ref-type="ref-list"}).

#### Sex {#CD005436-sec-0068}

Four trials only included males ([Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}; [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}), while the remaining 29 trials enrolled children of both sexes.

#### Geographical region {#CD005436-sec-0069}

Most included trials were conducted in Asia. Only three trials were conducted in Europe ([Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}), two in South America ([Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}), two in Africa ([Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}), one multicentre trial in Asia and Africa ([Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}), and one trial in Australia ([Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}). Thus, participants were from Bangladesh ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}), India ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}; [Fischer Walker 2006 IND](#CD005436-bbs2-0017){ref-type="ref-list"}; [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}; [Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}), Pakistan ([Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}; [Fischer Walker 2006 PAK](#CD005436-bbs2-0018){ref-type="ref-list"}), Nepal ([Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}), China ([Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}), Turkey ([Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}), Brazil ([Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}), Peru ([Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}), Ethiopia ([Fischer Walker 2006 ETH](#CD005436-bbs2-0016){ref-type="ref-list"}; [Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}), Nigeria ([Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}), Poland ([Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}), Italy ([Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}), Switzerland ([Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}), and Australia ([Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}).

#### Risk of zinc deficiency {#CD005436-sec-0070}

Most trials were conducted in countries ranked as at high risk of zinc deficiency ([IZiNCG 2004](#CD005436-bbs2-0204){ref-type="ref-list"}). Nine trials were conducted in countries at medium risk: Nepal ([Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}); Turkey ([Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}, [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}); Brazil ([Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}), China ([Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}), Iran ([Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}), Nigeria ([Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}), and Ethiopia ([Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}). Four trials were conducted in countries where zinc deficiency is considered rare: Poland ([Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}), Italy ([Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}), Switzerland ([Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}), and Australia ([Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}).

#### Zinc dose {#CD005436-sec-0071}

The most frequent zinc dose was 20 mg/day. Only three trials administered higher zinc doses: 40 mg/day ([Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}); 22 or 45 mg/day ([Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}); 20 and 40 mg respectively in children under and above six months of age ([Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}). Two trials, of which one was of children aged less than six months only, gave 10 mg/day zinc ([Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}).

Seven trials used different dosages based on the age of children (under and above six months of age): 5 mg and 10 mg ([Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}), 10 mg and 20 mg ([Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"} ), 20 and 40 mg ([Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"};); one trial used zinc at two different dosages (5 mg and 20 mg) in children aged less than six months ([Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}),

Seven trials used different doses depending on age (zinc \< 20 mg in infants and ≥ 20 mg in older children), but they did not report results separately for each treatment group ([Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}; [Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}; [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}). We classified these trials as \'not assignable\' and could not include them in the sensitivity analysis for zinc dose.

Three trials reported a per kilo dose: 1 mg/kg/day ([Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}); 2 mg/kg/day ([Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}); 3 mg/kg/day ([Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}). We were unable to include these trials in the subgroup analyses.

#### Type of zinc salt {#CD005436-sec-0072}

Eight trials used zinc acetate ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}; [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}), five used zinc gluconate ([Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}), and three did not specify ([Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}; [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}), while all the remaining trials used zinc sulphate.

#### Concomitant copper or iron supplementation {#CD005436-sec-0073}

One trial compared zinc alone versus zinc and copper versus placebo ([Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}).

#### Study setting {#CD005436-sec-0074}

Most trials were conducted in hospitals, with the exception of six community‐based trials ([Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}; [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}; [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}), and one trial was held in both hospital and community settings ([Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}).

#### Treatment regimen {#CD005436-sec-0075}

##### Treatment duration {#CD005436-sec-0076}

About half of trials administered zinc for two weeks. Of the remaining trials, one gave zinc for a total of four days ([Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}), three gave zinc for seven days after recovery ([Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}; [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}; [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}), four gave zinc until recovery ([Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}; [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}), one trial gave zinc for seven days ([Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}), and three trials gave zinc for 10 days ([Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}). Five trials were unclear in respect of duration of zinc supplementation ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}). One trial on adverse events administered only one dose of zinc ([Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}).

##### Formulation {#CD005436-sec-0077}

Most included trials administered zinc as syrup. Seven used dispersible tablets ([Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}; [Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}; [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}; [Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}: [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}), four used powder ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}), two mixed it with ORS ([Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}; [Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}), and one did not specify ([Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}).

##### Dose frequency {#CD005436-sec-0078}

Zinc was administered once a day in most of the included trials. It was administered twice a day in five trials ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}; [Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}), three times a day in six trials ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}), and together with ORS depending on stool frequency in two trials ([Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}; [Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}). One trial administered zinc twice a day to infants, and a single dose to children over six months ([Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}). Three trials did not specify the dose frequency ([Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}, [Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}).

##### Additional treatment {#CD005436-sec-0079}

Most trials administered zinc alone. Seven trials used zinc and multivitamin, which did not contain iron ([Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}; [Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}). One trial used zinc and vitamin A ([Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}). One trial used concomitant copper ([Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}).

### Excluded studies {#CD005436-sec-0080}

For this review update we excluded 11 studies after full‐text assessment. We have provided the total results of the study selection (that is, for the previous versions of this review plus this update) in [Table 5](#CD005436-tbl-0005){ref-type="table"}, and listed the reasons for exclusion of studies after full‐text assessment in the \'[Characteristics of excluded studies](#CD005436-sec-0134){ref-type="sec"}\' table.

Risk of bias in included studies {#CD005436-sec-0081}
--------------------------------

See [Figure 2](#CD005436-fig-0002){ref-type="fig"} and [Figure 3](#CD005436-fig-0003){ref-type="fig"} for the risk of bias in the included trials.

![\'Risk of bias\' graph: review authors\' judgements about each \'Risk of bias\' item presented as percentages across all included trials.](nCD005436-AFig-FIG02){#CD005436-fig-0002}

![\'Risk of bias\' summary: review authors\' judgements about each \'Risk of bias\' item for each included trial.](nCD005436-AFig-FIG03){#CD005436-fig-0003}

### Allocation {#CD005436-sec-0082}

Twenty‐six trials used adequate methods to generate the allocation sequence. The methods used in the other trials was either at unclear ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}), or at high risk of bias ([Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}).

Nineteen trials reported methods that assured adequate allocation concealment. Of the remaining trials, thirteen were at unclear risk of bias ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}; [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}; [Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}; [Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}), and one was at high risk of bias ([Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}).

### Blinding {#CD005436-sec-0083}

Twenty‐two trials were double blinded. Eight trials were at unclear risk of bias regarding the use of blinding ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}; [Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}; [Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}; [Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}), and three trials were at high risk of bias ([Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}; [Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}; [Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}).

### Incomplete outcome data {#CD005436-sec-0084}

Twenty‐one trials included more than 90% of the randomized participants in the analysis. Seven trials included less than 90% of the randomized participants, which we assessed as at high risk of bias ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}; [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}; [Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}; [Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}; [Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}; [Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}), and the five remaining trials were at unclear risk of bias ([Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}).

### Selective reporting {#CD005436-sec-0085}

Only three included trials were at low risk of bias regarding selective reporting ([Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}; [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}; [Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}). The risk of bias was unclear for all other included trials, and the most frequent reason for this was the fact that the trial was not registered.

### Other potential sources of bias {#CD005436-sec-0086}

No information was available to evaluate other sources of bias. Therefore we judged each of the included trials as at unclear risk of bias regarding other potential sources of bias.

Effects of interventions {#CD005436-sec-0087}
------------------------

See: [Table 1](#CD005436-tbl-0001){ref-type="table"}; [Table 2](#CD005436-tbl-0002){ref-type="table"}; [Table 3](#CD005436-tbl-0003){ref-type="table"}

### Comparison 1: Zinc versus placebo for children with acute diarrhoea {#CD005436-sec-0088}

#### Diarrhoea duration {#CD005436-sec-0089}

On average, the mean duration of diarrhoea in children given zinc was around 13 hours shorter than those given placebo (mean difference (MD) −13.42 hours, 95% confidence interval (CI) −20.52 to −6.31; 5096 children, 20 trials, 24 comparisons; [Analysis 1.1](#CD005436-fig-0009){ref-type="fig"}; [Figure 4](#CD005436-fig-0004){ref-type="fig"}), but there was substantial statistical heterogeneity between trials (I^2^ statistic = 84%).

![Zinc versus placebo for acute diarrhoea: diarrhoea duration (h)](nCD005436-AFig-FIG04){#CD005436-fig-0004}

In the primary analysis stratified by age, the benefit was only apparent in trials that recruited children over six months of age (MD −11.46 hours, 95% CI −19.72 to −3.19 hours; 2581 children, 9 trials; [Table 1](#CD005436-tbl-0001){ref-type="table"}; [Analysis 1.1](#CD005436-fig-0009){ref-type="fig"}; [Figure 4](#CD005436-fig-0004){ref-type="fig"}), and trials that recruited all age groups (MD −22.18 hours, 95% CI −32.57 to −11.78 hours; 1181 children, 9 trials, 10 comparisons). In trials that only recruited children less than six months of age, no effect was demonstrated (1334 children, 2 trials, 5 comparisons; [Table 2](#CD005436-tbl-0002){ref-type="table"}).

This age stratification did not adequately explain the statistical heterogeneity so we conducted a series of further subgroup analyses excluding the trials which only recruited children less than six months of age ([Analysis 1.2](#CD005436-fig-0010){ref-type="fig"} to [Analysis 1.9](#CD005436-fig-0017){ref-type="fig"}). None of these subgroupings adequately explained the heterogeneity, but several observations are worth noting.

When subgrouped by the nutritional status of participants, the smallest average effect was seen in trials that only recruited well‐nourished children, and the largest average effect in trials that only recruited children with signs of malnutrition ([Analysis 1.2](#CD005436-fig-0010){ref-type="fig"}).There was only one included trial from the African continent, and this trial failed to show a benefit ([Analysis 1.4](#CD005436-fig-0012){ref-type="fig"}).When subgrouped by the national risk of zinc deficiency, the smallest average effect was in countries at low risk of zinc deficiency ([Analysis 1.5](#CD005436-fig-0013){ref-type="fig"}).

#### Diarrhoea on days 3, 5, and 7 {#CD005436-sec-0090}

On average, treatment with zinc resulted in fewer children continuing to have diarrhoea at day three (risk ratio (RR) 0.77, 95% CI 0.69 to 0.86; 2063 children, 8 trials, 9 comparisons, [Analysis 1.10](#CD005436-fig-0018){ref-type="fig"}), at day five (RR 0.76, 95% CI 0.64 to 0.91; 2307 children, eight trials, [Analysis 1.11](#CD005436-fig-0019){ref-type="fig"}), and at day seven (RR 0.82, 95% CI 0.72 to 0.94; 5528 children, 10 trials, 13 comparisons; [Analysis 1.12](#CD005436-fig-0020){ref-type="fig"}; [Figure 5](#CD005436-fig-0005){ref-type="fig"}; [Table 1](#CD005436-tbl-0001){ref-type="table"}; [Table 2](#CD005436-tbl-0002){ref-type="table"}). For all the three outcomes there was significant statistical heterogeneity between trials.

![Zinc versus placebo for acute diarrhoea: diarrhoea on day 7](nCD005436-AFig-FIG05){#CD005436-fig-0005}

For diarrhoea at day seven we conducted a series of subgroup analyses to explore the heterogeneity ([Analysis 1.13](#CD005436-fig-0021){ref-type="fig"} to [Analysis 1.20](#CD005436-fig-0028){ref-type="fig"}), which found similar patterns as seen with duration of diarrhoea.

No subgrouping completely explained the statistical heterogeneity.There was no evidence of benefit in the single trial that recruited only children less than six months of age (1074 children, 1 trial, 3 comparisons; [Analysis 1.12](#CD005436-fig-0020){ref-type="fig"}). This was also the only trial conducted in the African continent.The average effect was largest in trials that only recruited children with signs of undernutrition ([Analysis 1.13](#CD005436-fig-0021){ref-type="fig"}).

#### Stool frequency {#CD005436-sec-0091}

There was no significant benefit of zinc on reducing stool frequency (RR −0.10, 95% CI −0.25 to 0.04; 2643 children, 7 trials, 10 comparisons; [Analysis 1.21](#CD005436-fig-0029){ref-type="fig"}). Heterogeneity was markedly reduced if results were stratified by age, and while no benefit of zinc was detected in children under six months of age (1334 children, 2 trials, 5 comparisons), zinc had a significant benefit in children older than six months (RR −0.32, 95% CI −0.58 to −0.06; 1235 children, 4 trials) and in the trial that recruited both age groups (RR −5.90, 95% CI −9.44 to −2.36; 74 children, 1 trial; [Analysis 1.21](#CD005436-fig-0029){ref-type="fig"}).

#### Stool output {#CD005436-sec-0092}

The included trials measured stool output using different units at different time points, thus we were unable to pool results ([Table 6](#CD005436-tbl-0006){ref-type="table"}). We expressed results are expressed as arithmetic mean difference (AMD) or geometric mean ratio (GMR) values.

###### Stool output: acute diarrhoea

  ------------------------------------------------------------------ ------------------------- ------------------------- ------------ ------------------ --------------------- ---------------------- -------------------- -----------------
  **Trial ID**                                                       **Outcome**               **Units**                 **Zinc**     **Placebo**        **Mean difference**   **Statistical test**                        

  **N**                                                              **Values**                **N**                     **Values**                                                                                        

  **Age \< 6 months**                                                                                                                                                                                                      

  [Brooks 2005a (5 mg)](#CD005436-bbs2-0008){ref-type="ref-list"}    Total (mL)                Mean (95% CI)             85           229\               45                    202\                   27\                  Not significant
                                                                                                                                      (180 to 256)                             (180 to 246)           (−23.3 to 77.3)^1^   

  [Brooks 2005a (20 mg)](#CD005436-bbs2-0007){ref-type="ref-list"}   Total (mL)                Mean (95% CI)             86           240\               44                    202\                   38\                  Not significant
                                                                                                                                      (200 to 266)                             (180 to 246)           (−8.6 to 84.6)^1^    

  **Age \> 6 months**                                                                                                                                                                                                      

  [Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}     Total (g)                 Mean (95% CI)             248          972\               247                   877\                   −95\                 Not significant
                                                                                                                                      (858 to 1087)                            (728 to 1026)          (−283 to 92)         

  [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}             Total (L)                 Mean (95% CI)             41           1.2\               43                    2.0\                   ‐ 0.8\               P \< 0.0001
                                                                                                                                      (0.6 to 1.8)                             (1.3 to 2.7)           (‐1.1 to 1.5)        

  [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}             Per day (ml/kg/day)       Mean (95% CI)             41           51.22\             43                    66.83\                 ‐ 15.61\             P = 0.0001
                                                                                                                                      (27.39 to 79.05)                         (42.41 to 71.25)       (‐22.9 to ‐8.2)      

  **Ages \< and \> 6 months**                                                                                                                                                                                              

  [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}        Total (g/kg)              Geometric mean (95% CI)   132          111\               134                   148\                   0.69\                P \< 0.05
                                                                                                                                      (86 to 147)                              (116 to 190)           (0.48 to 0.99)^2^    

  Per day (g/kg/day)                                                 Geometric mean (95% CI)   132                       62\          134                78\                   0.76\                  P \< 0.05            
                                                                                                                         (51 to 78)                      (68 to 91)            (0.59 to 0.98)^2^                           

  [Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}             Total (kg)                Mean (95% CI)             44           1.5\               36                    2.4\                   −0.9\                P = 0.0001
                                                                                                                                      (1.3 to 1.7)                             (2.2 to 2.6)           (−1.2 to −0.6)^1^    

  [Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}               Per day (g/kg/day)        Median (range)            37           238\               37                    329\                   −91\                 P = 0.06
                                                                                                                                      (35 to 2416)                             (32 to 1464)           (NA)                 
  ------------------------------------------------------------------ ------------------------- ------------------------- ------------ ------------------ --------------------- ---------------------- -------------------- -----------------

^1^Arithmetic mean difference (95% CI) for means.  ^2^Geometric mean ratio (95% CI) for geometric means, adjusted for confounders. (Stool output using zinc is 0.69 and 0.76 times that of participants using placebo, which means a 31% and 24% less stool output under zinc treatment.)

Abbreviations: CI: confidence interval; NA: not applicable.

One trial reported on children less than six months of age with no evidence of a difference ([Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}). Two trials reported on children more than six months of age with inconsistent results ([Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}; [Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}). Three trials reported on children aged less than and greater than six months: two of these trials showed a reduction in stool output with zinc ([Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}; [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}), while one trial showed no evidence of an effect ([Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}).

#### Hospitalization {#CD005436-sec-0093}

Two community trials reported no hospitalizations in the zinc group and only one in the placebo group ([Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}, 1074 participants under six months of age; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}, 276 children over six months of age).

#### Death {#CD005436-sec-0094}

The trials reported a low number of deaths without significant difference between the zinc group and placebo group ([Analysis 1.22](#CD005436-fig-0030){ref-type="fig"}).

#### Adverse events {#CD005436-sec-0095}

Vomiting was more common in those given zinc across all age groups (RR 1.54, 95% CI 1.28 to 1.85; 5942 children, 15 comparisons, 13 trials; [Figure 6](#CD005436-fig-0006){ref-type="fig"}). There was moderate heterogeneity among trials (P = 0.005; I² statistic = 56%), and differences in control event rates (from 0.4% to 13.5%). In one large trial with adequate allocation concealment that was designed to look at safety reports, vomiting was limited to one episode in most children and mainly occurred within 10 minutes of administration ([Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}). Two trials found no difference in time to resolution of vomiting between zinc and placebo, although we could not pool the results (mean duration 13.63 ± 10.33 hours versus 16.35 ± 11.34 hours, P = 0.1; [Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}; median duration 2 days (interquartile range (IQR) 1 to 3) versus 2.5 days (IQR 1 to 5), P \> 0.5; [Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}).

![Zinc versus placebo for acute diarrhoea: adverse events (vomiting)](nCD005436-AFig-FIG06){#CD005436-fig-0006}

One small trial reported a non‐statistically significant difference between the two treatment groups for difficulties in treatment administration (19/45 (45%) in the zinc group versus 20/44 (44%) in the placebo group ([Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}).

Three trials reported on copper levels, with no significant differences between the zinc and placebo groups. Two trials reported the mean change in serum copper on the last day of supplementation (seven and 14 days after recovery): −1.1 ± 5.5 µmol/dL in the zinc group versus −1.5 ± 4.2 µmol/dL in the placebo group in [Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}, and −41.2 ± 418.8 µg/dL in the zinc group versus −79.4 ± 429.2 µg/dL in the placebo group in [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}. Mean serum copper after 14 days was 121 mg/L in zinc group versus 127 mg/L in the control in [Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}.

No other side effects were reported.

#### Publication bias {#CD005436-sec-0096}

We constructed funnel plots for trials that reported diarrhoea duration ([Figure 7](#CD005436-fig-0007){ref-type="fig"}) and diarrhoea at day 7 ([Figure 8](#CD005436-fig-0008){ref-type="fig"}). The funnel plots are both asymmetric due to the absence of smaller trials at the base and, for diarrhoea at day 7, also at the right of the pooled estimate. Asymmetry in the funnel plot could result from possible selection bias where smaller studies reporting greater treatment benefit for the experimental group were published (publication bias). The gap in the bottom corner of the graph suggests that smaller studies without statistically significant effects remain unpublished. However, asymmetry in the funnel plot may also be due to other reasons, such as poor methodological quality in smaller studies leading to spuriously inflated effects in the treatment effect, true heterogeneity, sampling variation or chance ([Higgins 2011](#CD005436-bbs2-0200){ref-type="ref-list"}).

![Funnel plot of comparison: 1 Zinc versus placebo for children with acute diarrhoea, outcome: 1.1 Diarrhoea duration (hours).](nCD005436-AFig-FIG07){#CD005436-fig-0007}

![Funnel plot of comparison: 1 Zinc versus placebo for children with acute diarrhoea, outcome: 1.12 Diarrhoea on day 7.](nCD005436-AFig-FIG08){#CD005436-fig-0008}

#### Sensitivity analysis {#CD005436-sec-0097}

The sensitivity analysis against markers of methodological quality did not affect the direction of results. There was some loss of significance with diarrhoea duration, but overall the analysis did not change the point estimate of effects. The ITT analysis for worst‐case/best‐case scenarios did not alter the statistical significance of the results.

### Comparison 2: Zinc versus placebo for children with persistent diarrhoea {#CD005436-sec-0098}

All trials of persistent diarrhoea enrolled children aged over six months.

#### Diarrhoea duration {#CD005436-sec-0099}

On average, zinc supplementation reduced the duration of persistent diarrhoea by around 16 hours (MD −15.84 hours, 95% CI −25.43 to −6.24 hours; 529 children, 5 trials; [Analysis 2.1](#CD005436-fig-0033){ref-type="fig"}), with no evidence of heterogeneity.

#### Diarrhoea on days 3, 5, and 7 {#CD005436-sec-0100}

There was no evidence of a benefit with zinc in the one trial that reported on diarrhoea at days three ([Analysis 2.2](#CD005436-fig-0034){ref-type="fig"}) and five ([Analysis 2.3](#CD005436-fig-0035){ref-type="fig"}) ([Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}), and two trials that reported on diarrhoea at day seven ([Analysis 2.4](#CD005436-fig-0036){ref-type="fig"}; [Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}).

#### Stool frequency {#CD005436-sec-0101}

One small trial reported on stool frequency, [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}, but the result did not reach statistical significance (40 participants, [Analysis 2.5](#CD005436-fig-0037){ref-type="fig"}).

#### Stool output {#CD005436-sec-0102}

Stool output was measured using different units at different time points, thus we could not pool results ([Table 7](#CD005436-tbl-0007){ref-type="table"}). We expressed the results as the AMD or GMR. Two trials, [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"} and [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}, reported on children greater than six months of age, with five comparisons (Additional tables). Of these, one trial reported a significant reduction in cumulative stool output at day seven in the zinc group (AMD −338 mg/kg bodyweight, 95% CI −413.6 to −262.4 mg/kg bodyweight; P ≤ 0.001) ([Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}).

###### Stool output: persistent diarrhoea

  --------------------------------------------------------- ---------------------------------------- ---------------- ------------------- ------------------------- ---------------------- ----------------- -----------------
  **Trial ID**                                              **Outcome**                              **Zinc**         **Placebo**         **Mean difference ^1^**   **Statistical test**                     

  **N**                                                     **Mean (95% CI)**                        **N**            **Mean (95% CI)**                                                                      

  **Age \> 6 months**                                                                                                                                                                                        

  [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}   Per day of diarrhoea, day 1 (g/kg/day)   43               116.8\              44                        141.9\                 −25.1\            Not significant
                                                                                                                      (85.8 to 147.8)                               (91.2 to 192.6)        (−84.5 to 34.3)   

  Per day of diarrhoea, day 7 (g/kg/day)                    43                                       66.7\            44                  43.9\                     22.8\                  Not significant   
                                                                                                     (40.9 to 92.4)                       (32.1 to 55.7)            (−5.5 to 51.1)                           

  Per day of diarrhoea, day 14 (g/kg/day)                   43                                       24.9\            44                  27.8\                     ‐2.9\                  Not significant   
                                                                                                     (20.1 to 29.7)                       (18.5 to 37.1)            (−13.4 to 7.6)                           

  [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}   Cumulative day 1 (mg/kg)                 24               127\                24                        137\                   −10\              Not significant
                                                                                                                      (113 to 141)                                  (121 to 153)           (−31.6 to 11.6)   

  Cumulative day 7 (mg/kg)                                  24                                       528\             24                  866\                      −338\                  P ≤ 0.001         
                                                                                                     (472 to 584)                         (815 to 917)              (−413.6 to −262.4)                       
  --------------------------------------------------------- ---------------------------------------- ---------------- ------------------- ------------------------- ---------------------- ----------------- -----------------

^1^Arithmetic mean difference (95% CI) for means.

Abbreviations: CI: confidence interval; ID: identification.

#### Hospitalization {#CD005436-sec-0103}

The only community trial that reported on hospitalization did not observe any hospitalizations in the zinc or placebo group ([Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; 275 participants).

#### Death {#CD005436-sec-0104}

One trial reported one death in the zinc group compared to five deaths in the placebo group, out of 95 participants in each group ([Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}). Two trials did not observe deaths in any participants, irrespective of their allocated group ([Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}; [Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}).

#### Adverse events {#CD005436-sec-0105}

Four trials that reported on vomiting (505 children) showed no difference between the zinc and placebo groups ([Analysis 2.6](#CD005436-fig-0038){ref-type="fig"}): three of the trials reported no incidences of vomiting in either group ([Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}; [Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}; [Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}); one trial that used 3 mg/kg/day zinc for 14 days in moderately malnourished and severely malnourished children reported a significantly lower plasma copper levels in the zinc‐treated group by the end of the second week of therapy (56.2 ± 17.8 µg/dL versus 72.7 ± 18.3 µg/dL, P = 0.02; [Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}, 87 children).

#### Statistical heterogeneity {#CD005436-sec-0106}

There was heterogeneity between two trials for diarrhoea at day seven. This may be explained by differences in the geographical regions (India and Peru) or to other factors not explored in this Cochrane Review. Reporting of vomiting was heterogeneous between trials, and this may be due to difference in the population or in the definition of event, or to reporting bias.

#### Sensitivity analysis {#CD005436-sec-0107}

The sensitivity analyses did not affect the direction of results. There was some loss of significance with diarrhoea duration, but no changes in the point estimate of effects. An ITT analysis for worst‐case/best‐case scenarios did not alter the point estimate or the significance of results.

Discussion {#CD005436-sec-0108}
==========

Summary of main results {#CD005436-sec-0109}
-----------------------

Thirty‐three trials, enrolling 10,841 children, met our inclusion criteria. Most included trials were conducted in Asian countries where the risk of zinc deficiency is high.

### Acute diarrhoea {#CD005436-sec-0110}

There is currently not enough evidence from well conducted trials to be able to say whether zinc supplementation during acute diarrhoea reduces the number of deaths or the number of children hospitalized (*very low certainty evidence*).

In children aged greater than six months, zinc supplementation may shorten the duration of diarrhoea by around half a day (*low certainty evidence*), and probably reduces the number of children whose diarrhoea persists until day seven (*moderate certainty evidence*). In children with signs of moderate malnutrition the effect appears greater, reducing the duration of diarrhoea by around a day (*high certainty evidence*).

Conversely, in children less than six months of age, the available evidence suggests zinc supplementation may have no impact on the duration of diarrhoea (*low certainty evidence*), and may increase the proportion of children whose diarrhoea persists until day seven (*low certainty evidence*).

No trials reported serious adverse events, but zinc supplementation during acute diarrhoea causes vomiting in both age groups (*moderate certainty evidence*).

### Persistent diarrhoea {#CD005436-sec-0111}

In children with persistent diarrhoea, zinc supplementation probably shortens the duration of diarrhoea by around 16 hours (*moderate certainty evidence*).

Overall completeness and applicability of evidence {#CD005436-sec-0112}
--------------------------------------------------

This Cochrane Review showed that zinc overall reduced the duration of acute diarrhoea. However, most trials were conducted in populations with moderate to high risk of zinc deficiency (Asia, Africa, children over six months of age and with some degree of malnutrition). Transferability of these results to other countries is therefore likely to depend on local risk of zinc deficiency and other population characteristics such as the degree of malnutrition and breastfeeding habits. The few trials conducted in populations at low risk of zinc deficiency, namely well‐nourished children in countries and continents where zinc deficiency is uncommon (Europe, Australia), overall showed no benefit of zinc.

Most trials were conducted in hospital where participants are more likely to adhere to the intervention, but some community trials also showed a benefit with zinc, which suggests that zinc could be used both at hospital and at community level.

The observed increase in vomiting was consistent across trials in all age groups with one large trial reporting that vomiting was limited to one episode in most children and mainly occurring within 10 minutes of administration ([Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}). Zinc has a metallic after‐taste, and development of a more palatable formulation may minimize this adverse effect.

Quality of the evidence {#CD005436-sec-0113}
-----------------------

We assessed the certainty of the evidence using the GRADE methodology and displayed it in three \'Summary of findings\' tables ([Table 1](#CD005436-tbl-0001){ref-type="table"}; [Table 2](#CD005436-tbl-0002){ref-type="table"}; [Table 3](#CD005436-tbl-0003){ref-type="table"}).

In general, the methodological quality of the trials included in this review was good.

The evidence for benefits on diarrhoea duration in children aged greater than six months of age is of low to moderate certainty. This implies that we can have some confidence in the results but further research may alter the estimates of benefit and harm. The main reasons to downgrade were \'quality of trials\' and \'inconsistency\' in the results. Heterogeneity between trials was often high. This is perhaps not surprising given the variations in populations, settings, and interventions. We were unable to completely explain this heterogeneity through subgroup analysis, and so our confidence that zinc supplementation can be broadly applied was decreased.

Most trials were conducted in hospitals where death rates were low, and were consequently not powered to detect an effect on mortality. Large community trials are needed to explore whether zinc treatment for diarrhoea reduces hospitalization and death.

Potential biases in the review process {#CD005436-sec-0114}
--------------------------------------

We attempted to limit bias by following the rigorous methods provided by the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#CD005436-bbs2-0200){ref-type="ref-list"}). We conducted an extensive search for studies, including ongoing studies. We only included peer‐reviewed trials in this review. Two review authors independently scrutinized the studies, assessed them for eligibility, extracted data, inserted data into RevMan 5 ([Review Manager 5](#CD005436-bbs2-0219){ref-type="ref-list"}), and double checked the final version of the review. The findings of the funnel plots may suggest publication bias. However, asymmetry in the funnel plots may also be due to other reasons, such as poor methodological quality in smaller studies leading to spuriously inflated effects, true heterogeneity in the treatment effect, sampling variation, or chance ([Higgins 2011](#CD005436-bbs2-0200){ref-type="ref-list"}).

Agreements and disagreements with other studies or reviews {#CD005436-sec-0115}
----------------------------------------------------------

Our results agree with those of other systematic reviews of zinc for treating children that have diarrhoea ([Bhutta 2000b](#CD005436-bbs2-0189){ref-type="ref-list"}; [Lukacik 2008](#CD005436-bbs2-0212){ref-type="ref-list"}; [Patro 2008](#CD005436-bbs2-0215){ref-type="ref-list"}; [Haider 2009](#CD005436-bbs2-0198){ref-type="ref-list"}; [Liberato 2015](#CD005436-bbs2-0209){ref-type="ref-list"}; [Zou 2015](#CD005436-bbs2-0227){ref-type="ref-list"}), except for the finding of no effect of zinc in children aged less than six months, and in populations at low risk of zinc deficiency. Compared to the other recent reviews ([Liberato 2015](#CD005436-bbs2-0209){ref-type="ref-list"}; [Zou 2015](#CD005436-bbs2-0227){ref-type="ref-list"}; [Lazzerini 2016](#CD005436-bbs2-0208){ref-type="ref-list"}), this Cochrane Review includes several new trials, includes a more extensive subgroup analysis, and reports on diarrhoea at different time points, diarrhoea severity, death, and adverse events.

The results of this Cochrane Review in children over six months of age support the current WHO/UNICEF policy to give zinc to children with diarrhoea ([WHO/UNICEF 2004](#CD005436-bbs2-0223){ref-type="ref-list"}), while currently there are no evidence from randomized controlled trials to provide zinc in children younger than six months of age.

Authors\' conclusions {#CD005436-sec-0116}
=====================

Implications for practiceIn areas where diarrhoea is an important cause of child mortality, and the prevalence of zinc deficiency or mild/moderate malnutrition is high, zinc may be of benefit in children with diarrhoea aged six months or more.

Implications for researchCauses of heterogeneity in the effect of zinc in children over six months should be further explored, and further research is necessary to justify continued supplementation in children less than six months of age and in children with low risk of zinc deficiency.

What\'s new {#CD005436-sec-0121}
===========

**DateEventDescription**25 April 2017AmendedWe have amended the GRADE assessment for two outcomes, duration of diarrhea and diarrhea on day 7 for children aged less than 6 months with acute diarrhoea and treated with zinc, which we had scored incorrectly in the review update. We had stated that these outcomes had a GRADE score of moderate. However, we had downgraded the certainty of the evidence by 2, and thus the certainty of the evidence was low. We have amended the certainty of the evidence for these two outcomes to low in \'Summary of findings\' table 2 and the review text.

History {#CD005436-sec-0122}
=======

Protocol first published: Issue 3, 2005  Review first published: Issue 3, 2008

**DateEventDescription**19 December 2016New citation required but conclusions have not changedWe included 33 trials in total in this review update, of which nine were new trials. We updated the \'Summary of findings\' tables according to the GRADE approach, and included a PRISMA study flow diagram and funnel plots.19 December 2016New search has been performedWe amended the author team. Luca Ronfani stepped down as an author, and Humphrey Wanzira joined as an author. We updated the literature search to 30 September 2016, and nine new trials met the inclusion criteria of the review update.6 December 2012New citation required but conclusions have not changedWe corrected the Abstract.6 December 2012AmendedAn error was spotted in the abstract (number of participants and number of studies was incorrect). We have corrected this and republished the review to ensure the correct details are documented.22 March 2012New search has been performedWe updated the search on 20 February 2012, and included two new trials. We updated the [Background](#CD005436-sec-0024){ref-type="sec"} and undertook a more detailed assessment of the risk of bias in all included trials. We updated the \'Summary of findings\' tables according to the GRADE methodology.22 March 2012New citation required but conclusions have not changedUpdate.11 February 2011New search has been performedWe updated the search on 1 December 2010, and included four new trials. We updated the [Background](#CD005436-sec-0024){ref-type="sec"} and performed a more detailed assessment of the risk of bias in all included trials. We added \'Summary of findings\' tables according to the GRADE methodology.

We thank Victoria Lutje for support in the search strategy, and Deirdre Walshe and David Sinclair for their help in reviewing the text. We acknowledge Luca Ronfani for his contributions to previously published versions of this Cochrane Review. The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this review do not necessarily reflect UK government policy.

###### Zinc versus placebo for children with acute diarrhoea

  Outcome or subgroup title                                                                                            No. of studies   No. of participants   Statistical method                     Effect size
  -------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- -------------------------------------- ---------------------------
  [1 Diarrhoea duration (hours)](#CD005436-fig-0009){ref-type="fig"}                                                   24               5096                  Mean Difference (IV, Random, 95% CI)   ‐13.42 \[‐20.52, ‐6.31\]
  1.1 Age \< 6 months                                                                                                  5                1334                  Mean Difference (IV, Random, 95% CI)   5.23 \[‐2.00, 14.45\]
  1.2 Age \> 6 months                                                                                                  9                2581                  Mean Difference (IV, Random, 95% CI)   ‐11.46 \[‐19.72, ‐3.19\]
  1.3 Ages both \< and \> 6 months                                                                                     10               1181                  Mean Difference (IV, Random, 95% CI)   ‐22.18 \[‐32.57, ‐11.78\]
  [2 Diarrhoea duration (hours): subgrouped by nutritional status](#CD005436-fig-0010){ref-type="fig"}                 17               3518                  Mean Difference (IV, Random, 95% CI)   ‐17.54 \[‐25.49, ‐9.58\]
  2.1 Nutritional status: only well‐nourished                                                                          2                406                   Mean Difference (IV, Random, 95% CI)   ‐6.79 \[‐23.84, 10.26\]
  2.2 Nutritional status: well‐nourished plus moderately malnourished                                                  10               2693                  Mean Difference (IV, Random, 95% CI)   ‐15.46 \[‐25.55, ‐5.36\]
  2.3 Nutritional status: malnourished                                                                                 5                419                   Mean Difference (IV, Random, 95% CI)   ‐26.39 \[‐36.54, ‐16.23\]
  [3 Diarrhoea duration (hours): subgrouped by sex](#CD005436-fig-0011){ref-type="fig"}                                18               3621                  Mean Difference (IV, Random, 95% CI)   ‐17.33 \[‐25.03, ‐9.62\]
  3.1 Sex: male                                                                                                        3                430                   Mean Difference (IV, Random, 95% CI)   ‐22.35 \[‐36.40, ‐8.31\]
  3.2 Sex: male and female                                                                                             15               3191                  Mean Difference (IV, Random, 95% CI)   ‐16.13 \[‐24.71, ‐7.55\]
  [4 Diarrhoea duration (hours); subgrouped by continent](#CD005436-fig-0012){ref-type="fig"}                          18               3621                  Mean Difference (IV, Random, 95% CI)   ‐17.33 \[‐25.03, ‐9.62\]
  4.1 Continent: Africa                                                                                                1                60                    Mean Difference (IV, Random, 95% CI)   ‐2.40 \[‐33.25, 28.45\]
  4.2 Continent: Asia                                                                                                  13               3205                  Mean Difference (IV, Random, 95% CI)   ‐19.01 \[‐28.19, ‐9.82\]
  4.3 Continent: South America                                                                                         1                74                    Mean Difference (IV, Random, 95% CI)   ‐31.20 \[‐46.43, ‐15.97\]
  4.4 Continent: Europe                                                                                                2                224                   Mean Difference (IV, Random, 95% CI)   ‐10.19 \[‐34.29, 13.91\]
  4.5 Continent: Australia                                                                                             1                58                    Mean Difference (IV, Random, 95% CI)   ‐2.40 \[‐20.93, 16.13\]
  [5 Diarrhoea duration (hours): subgrouped by national risk of zinc deficiency](#CD005436-fig-0013){ref-type="fig"}   16               3253                  Mean Difference (IV, Random, 95% CI)   ‐16.99 \[‐25.49, ‐8.50\]
  5.1 Region: countries ranked as high risk of zinc deficiency                                                         8                2535                  Mean Difference (IV, Random, 95% CI)   ‐14.97 \[‐26.21, ‐3.72\]
  5.2 Region: countries ranked as medium risk of zinc deficiency                                                       5                436                   Mean Difference (IV, Random, 95% CI)   ‐25.92 \[‐44.80, ‐7.04\]
  5.3 Region: countries ranked as low risk of zinc deficiency                                                          3                282                   Mean Difference (IV, Random, 95% CI)   ‐7.63 \[‐22.74, 7.48\]
  [6 Diarrhoea duration (hours): subgrouped by zinc dose](#CD005436-fig-0014){ref-type="fig"}                          13               2018                  Mean Difference (IV, Random, 95% CI)   ‐20.24 \[‐28.84, ‐11.63\]
  6.1 Zinc dose:≤ 20 mg                                                                                                9                976                   Mean Difference (IV, Random, 95% CI)   ‐18.45 \[‐30.19, ‐6.71\]
  6.2 Zinc dose: \> 20 mg                                                                                              4                1042                  Mean Difference (IV, Random, 95% CI)   ‐23.33 \[‐38.30, ‐8.35\]
  [7 Diarrhoea duration (hours): subgrouped by zinc type](#CD005436-fig-0015){ref-type="fig"}                          16               3454                  Mean Difference (IV, Random, 95% CI)   ‐16.50 \[‐25.11, ‐7.89\]
  7.1 Zinc type: zinc acetate                                                                                          3                875                   Mean Difference (IV, Random, 95% CI)   ‐30.55 \[‐49.29, ‐11.82\]
  7.2 Zinc type: gluconate                                                                                             2                908                   Mean Difference (IV, Random, 95% CI)   ‐14.51 \[‐30.84, 1.81\]
  7.3 Zinc type: zinc sulphate                                                                                         11               1671                  Mean Difference (IV, Random, 95% CI)   ‐13.21 \[‐24.16, ‐2.27\]
  [8 Diarrhoea duration (hours): subgrouped by study setting](#CD005436-fig-0016){ref-type="fig"}                      18               3621                  Mean Difference (IV, Random, 95% CI)   ‐17.33 \[‐25.03, ‐9.62\]
  8.1 Study setting: hospital                                                                                          15               2468                  Mean Difference (IV, Random, 95% CI)   ‐17.86 \[‐27.01, ‐8.70\]
  8.2 Study setting:community                                                                                          3                1153                  Mean Difference (IV, Random, 95% CI)   ‐12.65 \[‐21.76, ‐3.54\]
  [9 Diarrhoea duration (hours): subgrouped by concomitant treatment](#CD005436-fig-0017){ref-type="fig"}              18               3777                  Mean Difference (IV, Random, 95% CI)   ‐15.68 \[‐23.53, ‐7.82\]
  9.1 Concomitant treatment: zinc alone                                                                                17               3394                  Mean Difference (IV, Random, 95% CI)   ‐16.95 \[‐24.85, ‐9.05\]
  9.2 Concomitant treatment: zinc plus copper                                                                          1                383                   Mean Difference (IV, Random, 95% CI)   2.20 \[‐5.08, 9.48\]
  [10 Diarrhoea on day 3](#CD005436-fig-0018){ref-type="fig"}                                                          9                2063                  Risk Ratio (M‐H, Fixed, 95% CI)        0.77 \[0.69, 0.86\]
  10.1 Age \> 6 months                                                                                                 4                1599                  Risk Ratio (M‐H, Fixed, 95% CI)        0.83 \[0.72, 0.94\]
  10.2 Ages both \< and \> 6 months                                                                                    5                464                   Risk Ratio (M‐H, Fixed, 95% CI)        0.66 \[0.56, 0.79\]
  [11 Diarrhoea on day 5](#CD005436-fig-0019){ref-type="fig"}                                                          8                2307                  Risk Ratio (M‐H, Fixed, 95% CI)        0.76 \[0.64, 0.91\]
  11.1 Age \> 6 months                                                                                                 3                1384                  Risk Ratio (M‐H, Fixed, 95% CI)        0.72 \[0.52, 1.01\]
  11.2 Ages both \< and \> 6 months                                                                                    5                923                   Risk Ratio (M‐H, Fixed, 95% CI)        0.78 \[0.64, 0.96\]
  [12 Diarrhoea on day 7](#CD005436-fig-0020){ref-type="fig"}                                                          13               5528                  Risk Ratio (M‐H, Fixed, 95% CI)        0.82 \[0.72, 0.94\]
  12.1 Age \< 6 months                                                                                                 3                1074                  Risk Ratio (M‐H, Fixed, 95% CI)        1.24 \[0.99, 1.54\]
  12.2 Age \> 6 months                                                                                                 6                3865                  Risk Ratio (M‐H, Fixed, 95% CI)        0.73 \[0.61, 0.88\]
  12.3 Ages both \< and \> 6 months                                                                                    4                589                   Risk Ratio (M‐H, Fixed, 95% CI)        0.31 \[0.18, 0.52\]
  [13 Diarrhoea on day 7: subgrouped by nutritional status](#CD005436-fig-0021){ref-type="fig"}                        10                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  13.1 Nutritional status: only well‐nourished                                                                         1                141                   Risk Ratio (M‐H, Fixed, 95% CI)        0.35 \[0.04, 3.26\]
  13.2 Nutritional status: well‐nourished plus moderately malnourished                                                 6                4075                  Risk Ratio (M‐H, Fixed, 95% CI)        0.72 \[0.60, 0.86\]
  13.3 Nutritional status: malnourished                                                                                3                238                   Risk Ratio (M‐H, Fixed, 95% CI)        0.37 \[0.22, 0.61\]
  [14 Diarrhoea on day 7: subgrouped by sex](#CD005436-fig-0022){ref-type="fig"}                                       10                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  14.1 Sex: male                                                                                                       1                266                   Risk Ratio (M‐H, Fixed, 95% CI)        0.11 \[0.01, 0.88\]
  14.2 Sex: male and female                                                                                            9                4188                  Risk Ratio (M‐H, Fixed, 95% CI)        0.68 \[0.58, 0.81\]
  [15 Diarrhoea on day 7: subgrouped by continent](#CD005436-fig-0023){ref-type="fig"}                                 10                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  15.1 Region: Asia                                                                                                    9                4313                  Risk Ratio (M‐H, Fixed, 95% CI)        0.67 \[0.56, 0.79\]
  15.2 Region: Europe                                                                                                  1                141                   Risk Ratio (M‐H, Fixed, 95% CI)        0.35 \[0.04, 3.26\]
  [16 Diarrhoea on day 7: subgrouped by national risk of zinc deficiency](#CD005436-fig-0024){ref-type="fig"}          10                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  16.1 Region: countries ranked as high risk of zinc deficiency                                                        6                3240                  Risk Ratio (M‐H, Fixed, 95% CI)        0.75 \[0.62, 0.92\]
  16.2 Region: countries ranked as medium risk of zinc deficiency                                                      3                1073                  Risk Ratio (M‐H, Fixed, 95% CI)        0.49 \[0.35, 0.68\]
  16.3 Region: countries ranked as low risk of zinc deficiency                                                         1                141                   Risk Ratio (M‐H, Fixed, 95% CI)        0.35 \[0.04, 3.26\]
  [17 Diarrhoea on day 7: subgrouped by zinc dose](#CD005436-fig-0025){ref-type="fig"}                                 9                                      Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  17.1 Zinc dose: 20 mg                                                                                                8                3154                  Risk Ratio (M‐H, Fixed, 95% CI)        0.62 \[0.51, 0.74\]
  17.2 Zinc dose: \>20mg                                                                                               1                805                   Risk Ratio (M‐H, Fixed, 95% CI)        0.67 \[0.38, 1.19\]
  [18 Diarrhoea on day 7: subgrouped by zinc type](#CD005436-fig-0026){ref-type="fig"}                                 10                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  18.1 Zinc type: zinc acetate                                                                                         3                1628                  Risk Ratio (M‐H, Fixed, 95% CI)        0.60 \[0.45, 0.79\]
  18.2 Zinc type:gluconate                                                                                             1                805                   Risk Ratio (M‐H, Fixed, 95% CI)        0.67 \[0.38, 1.19\]
  18.3 Zinc type: zinc sulphate                                                                                        6                2021                  Risk Ratio (M‐H, Fixed, 95% CI)        0.72 \[0.57, 0.90\]
  [19 Diarrhoea on day 7: subgrouped by study setting](#CD005436-fig-0027){ref-type="fig"}                             10                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  19.1 Study setting: hospital                                                                                         8                2758                  Risk Ratio (M‐H, Fixed, 95% CI)        0.69 \[0.56, 0.84\]
  19.2 Study setting: community                                                                                        2                1696                  Risk Ratio (M‐H, Fixed, 95% CI)        0.61 \[0.44, 0.85\]
  [20 Diarrhoea on day 7: subgrouped by concomitant treatment](#CD005436-fig-0028){ref-type="fig"}                     11                                     Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  20.1 Concomitant treatment: zinc alone                                                                               10               4330                  Risk Ratio (M‐H, Fixed, 95% CI)        0.65 \[0.55, 0.78\]
  20.2 Concomitant treatment: zinc plus copper                                                                         1                383                   Risk Ratio (M‐H, Fixed, 95% CI)        1.03 \[0.43, 2.45\]
  [21 Stool frequency (stools /day)](#CD005436-fig-0029){ref-type="fig"}                                               10               2643                  Mean Difference (IV, Fixed, 95% CI)    ‐0.10 \[‐0.25, 0.04\]
  21.1 Age \< 6 months                                                                                                 5                1334                  Mean Difference (IV, Fixed, 95% CI)    0.0 \[‐0.17, 0.17\]
  21.2 Age \> 6 months                                                                                                 4                1235                  Mean Difference (IV, Fixed, 95% CI)    ‐0.32 \[‐0.58, ‐0.06\]
  21.3 Ages both \< and \> 6 months                                                                                    1                74                    Mean Difference (IV, Fixed, 95% CI)    ‐5.9 \[‐9.44, ‐2.36\]
  [22 Death](#CD005436-fig-0030){ref-type="fig"}                                                                       8                2609                  Risk Ratio (M‐H, Fixed, 95% CI)        0.31 \[0.09, 1.07\]
  22.1 Age \< 6 months                                                                                                 2                1334                  Risk Ratio (M‐H, Fixed, 95% CI)        1.00 \[0.06, 15.89\]
  22.2 Age \> 6 months                                                                                                 5                1134                  Risk Ratio (M‐H, Fixed, 95% CI)        0.29 \[0.04, 2.20\]
  22.3 Ages both \< and \> 6 months                                                                                    1                141                   Risk Ratio (M‐H, Fixed, 95% CI)        0.19 \[0.02, 1.55\]
  [23 Adverse events (vomiting)](#CD005436-fig-0031){ref-type="fig"}                                                   15               5942                  Risk Ratio (M‐H, Random, 95% CI)       1.54 \[1.28, 1.85\]
  23.1 Age \< 6 months                                                                                                 3                1334                  Risk Ratio (M‐H, Random, 95% CI)       1.54 \[1.05, 2.24\]
  23.2 Age \> 6 months                                                                                                 6                2605                  Risk Ratio (M‐H, Random, 95% CI)       1.57 \[1.32, 1.86\]
  23.3 Ages both \< and \> 6 months                                                                                    6                2003                  Risk Ratio (M‐H, Random, 95% CI)       1.63 \[1.14, 2.34\]
  [24 Difficulties in treatment administration](#CD005436-fig-0032){ref-type="fig"}                                    1                87                    Odds Ratio (M‐H, Fixed, 95% CI)        1.03 \[0.44, 2.41\]

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 1 Diarrhoea duration (hours).](nCD005436-CMP-001-01){#CD005436-fig-0009}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 2 Diarrhoea duration (hours): subgrouped by nutritional status.](nCD005436-CMP-001-02){#CD005436-fig-0010}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 3 Diarrhoea duration (hours): subgrouped by sex.](nCD005436-CMP-001-03){#CD005436-fig-0011}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 4 Diarrhoea duration (hours); subgrouped by continent.](nCD005436-CMP-001-04){#CD005436-fig-0012}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 5 Diarrhoea duration (hours): subgrouped by national risk of zinc deficiency.](nCD005436-CMP-001-05){#CD005436-fig-0013}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 6 Diarrhoea duration (hours): subgrouped by zinc dose.](nCD005436-CMP-001-06){#CD005436-fig-0014}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 7 Diarrhoea duration (hours): subgrouped by zinc type.](nCD005436-CMP-001-07){#CD005436-fig-0015}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 8 Diarrhoea duration (hours): subgrouped by study setting.](nCD005436-CMP-001-08){#CD005436-fig-0016}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 9 Diarrhoea duration (hours): subgrouped by concomitant treatment.](nCD005436-CMP-001-09){#CD005436-fig-0017}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 10 Diarrhoea on day 3.](nCD005436-CMP-001-10){#CD005436-fig-0018}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 11 Diarrhoea on day 5.](nCD005436-CMP-001-11){#CD005436-fig-0019}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 12 Diarrhoea on day 7.](nCD005436-CMP-001-12){#CD005436-fig-0020}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 13 Diarrhoea on day 7: subgrouped by nutritional status.](nCD005436-CMP-001-13){#CD005436-fig-0021}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 14 Diarrhoea on day 7: subgrouped by sex.](nCD005436-CMP-001-14){#CD005436-fig-0022}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 15 Diarrhoea on day 7: subgrouped by continent.](nCD005436-CMP-001-15){#CD005436-fig-0023}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 16 Diarrhoea on day 7: subgrouped by national risk of zinc deficiency.](nCD005436-CMP-001-16){#CD005436-fig-0024}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 17 Diarrhoea on day 7: subgrouped by zinc dose.](nCD005436-CMP-001-17){#CD005436-fig-0025}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 18 Diarrhoea on day 7: subgrouped by zinc type.](nCD005436-CMP-001-18){#CD005436-fig-0026}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 19 Diarrhoea on day 7: subgrouped by study setting.](nCD005436-CMP-001-19){#CD005436-fig-0027}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 20 Diarrhoea on day 7: subgrouped by concomitant treatment.](nCD005436-CMP-001-20){#CD005436-fig-0028}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 21 Stool frequency (stools /day).](nCD005436-CMP-001-21){#CD005436-fig-0029}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 22 Death.](nCD005436-CMP-001-22){#CD005436-fig-0030}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 23 Adverse events (vomiting).](nCD005436-CMP-001-23){#CD005436-fig-0031}

![Analysis\
Comparison 1 Zinc versus placebo for children with acute diarrhoea, Outcome 24 Difficulties in treatment administration.](nCD005436-CMP-001-24){#CD005436-fig-0032}

###### Zinc versus placebo for children with persistent diarrhoea

  Outcome or subgroup title                                              No. of studies   No. of participants   Statistical method                    Effect size
  ---------------------------------------------------------------------- ---------------- --------------------- ------------------------------------- --------------------------
  [1 Diarrhoea duration (hours)](#CD005436-fig-0033){ref-type="fig"}     5                529                   Mean Difference (IV, Fixed, 95% CI)   ‐15.84 \[‐25.43, ‐6.24\]
  1.1 Age \> 6 months                                                    4                388                   Mean Difference (IV, Fixed, 95% CI)   ‐16.01 \[‐26.16, ‐5.86\]
  1.2 Ages both \< and \> 6 months                                       1                141                   Mean Difference (IV, Fixed, 95% CI)   ‐14.40 \[‐43.77, 14.97\]
  [2 Diarrhoea on day 3](#CD005436-fig-0034){ref-type="fig"}             1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Totals not selected
  2.1 Age \> 6 months                                                    1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  [3 Diarrhoea on day 5](#CD005436-fig-0035){ref-type="fig"}             1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Totals not selected
  3.1 Age \> 6 months                                                    1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  [4 Diarrhoea on day 7](#CD005436-fig-0036){ref-type="fig"}             2                221                   Risk Ratio (M‐H, Fixed, 95% CI)       0.52 \[0.27, 1.02\]
  4.1 Age \> 6 months                                                    2                221                   Risk Ratio (M‐H, Fixed, 95% CI)       0.52 \[0.27, 1.02\]
  [5 Stool frequency (stools/day)](#CD005436-fig-0037){ref-type="fig"}   1                                      Mean Difference (IV, Fixed, 95% CI)   Totals not selected
  5.1 Age \> 6 months                                                    1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [6 Adverse events (vomiting)](#CD005436-fig-0038){ref-type="fig"}      4                505                   Risk Ratio (M‐H, Fixed, 95% CI)       1.97 \[0.37, 10.59\]
  6.1 Age \> 6 months                                                    3                364                   Risk Ratio (M‐H, Fixed, 95% CI)       1.97 \[0.37, 10.59\]
  6.2 Ages both \< and \> 6 months                                       1                141                   Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]

![Analysis\
Comparison 2 Zinc versus placebo for children with persistent diarrhoea, Outcome 1 Diarrhoea duration (hours).](nCD005436-CMP-002-01){#CD005436-fig-0033}

![Analysis\
Comparison 2 Zinc versus placebo for children with persistent diarrhoea, Outcome 2 Diarrhoea on day 3.](nCD005436-CMP-002-02){#CD005436-fig-0034}

![Analysis\
Comparison 2 Zinc versus placebo for children with persistent diarrhoea, Outcome 3 Diarrhoea on day 5.](nCD005436-CMP-002-03){#CD005436-fig-0035}

![Analysis\
Comparison 2 Zinc versus placebo for children with persistent diarrhoea, Outcome 4 Diarrhoea on day 7.](nCD005436-CMP-002-04){#CD005436-fig-0036}

![Analysis\
Comparison 2 Zinc versus placebo for children with persistent diarrhoea, Outcome 5 Stool frequency (stools/day).](nCD005436-CMP-002-05){#CD005436-fig-0037}

![Analysis\
Comparison 2 Zinc versus placebo for children with persistent diarrhoea, Outcome 6 Adverse events (vomiting).](nCD005436-CMP-002-06){#CD005436-fig-0038}

Characteristics of included studies \[ordered by study ID\] {#CD005436-sec-0133}
===========================================================

[Al‐Sonboli 2003](#CD005436-bbs2-0001){ref-type="ref-list"}MethodsRandomized controlled trial (RCT)ParticipantsNumber of participants (N): 81 participants\
Inclusion criteria: age 3 to 60 months; diarrhoea \< 7 days, or 1 or more loose stool containing blood in the previous 24 hours and at least mild dehydration\
Exclusion criteria: suspected or confirmed severe systemic infections; antimicrobial or antidiarrhoeal treatment within 72 hours before admission; severe malnutrition (\< 60% median for weight for age of the National Center for Health Statistic (NCHC) standards)InterventionsZinc sulphate: 22.5 mg (3 to 6 months) or 45 mg (7 to 60 months).Placebo.OutcomesAverage duration of diarrhoea.Stool frequency.NotesLocation: Brazil\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a random numbers table to randomize participants.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any details regarding allocation concealment.Blinding (performance bias and detection bias)   All outcomesLow riskThis trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk8.6% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available.[Bahl 2002](#CD005436-bbs2-0002){ref-type="ref-list"}MethodsRCTParticipantsN: 1219 participants\
Inclusion criteria: age 6 to 35 months; acute diarrhoea (less than 4 days duration)\
Exclusion criteria: visible blood in stools; likely to emigrate in the next 4 weeks; required hospitalization; previously enrolled; sibling concurrently enrolled; refusal of consentInterventionsZinc gluconate 30 mg (≥ 12 months) or 15 mg (\< 12 months).Placebo.OutcomesAverage duration of diarrhoea.Diarrhoea at day 3.Diarrhoea at day 5.Diarrhoea at day 7.Stool frequency.Adverse events (vomiting).NotesLocation: India\
Setting: community***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThis trial used computer‐generated randomization lists.Allocation concealment (selection bias)Low riskAn independent individual who was not involved in participant enrolment labelled the glass bottles that contained the products with the participant's number that corresponded to the randomization list. Randomization codes were secured until the completion of data collection and initial analysis. There was no difference between zinc and the placebo in appearance; a minor metallic aftertaste of zinc was hardly detectable.Blinding (performance bias and detection bias)   All outcomesLow riskFour‐blinded (participant, intervention provider, data collector, data analyst).Incomplete outcome data (attrition bias)   All outcomesLow risk2% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no available protocol.Other biasUnclear riskThere was no further information available.[Bhatnagar 2004a](#CD005436-bbs2-0003){ref-type="ref-list"}MethodsRCTParticipantsN: 287 participants\
Inclusion criteria: male; 3 to 36 months; acute diarrhoea (\< 72 hours) with mild dehydration\
Exclusion criteria: severe malnutrition (weight/height \< 65% of NCHS median); visible blood in stool; severe systemic illnessInterventionsZinc sulphate: 15 mg (\< 12 months) or 30 mg (\> 12 months) syrup.Placebo.\
Both groups: multivitaminOutcomesAverage duration of diarrhoea.Diarrhoea at day 5.Diarrhoea at day 7.Stool output.Adverse events (vomiting).Adverse events (copper levels).NotesLocation: India\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used a table of random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskCentral randomization was performed at a site remote from trial location (World Health Organization (WHO), Geneva).Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk7% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no available protocol.Other biasUnclear riskThere was no further information available on other risks of bias.[Bhutta 1999](#CD005436-bbs2-0004){ref-type="ref-list"}MethodsRCTParticipantsN: 87 participants\
Inclusion criteria: 6 to 36 months; persistent diarrhoea (\> 4 unformed stools/day for at least 14 days); malnutrition (weight‐for‐age z score \< −2.0)\
Exclusion criteria: kwashiorkor; clinical signs of vitamin A or zinc deficiency; needing intravenous fluids or unable to tolerate oral feeds after a 24‐hour period of stabilizationInterventionsZinc sulphate: 3 mg/kg/day.Placebo.\
Both groups: multivitaminsOutcomesAverage duration of diarrhoea.Stool output.Adverse events (copper levels).NotesLocation: Pakistan\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom numbers table.Allocation concealment (selection bias)Low riskAn independent pharmacy performed central randomization; the pharmacy maintained the table block randomization.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesHigh risk11% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available.[Boran 2006](#CD005436-bbs2-0005){ref-type="ref-list"}MethodsRCTParticipantsN: 280 participants\
Inclusion criteria: acute diarrhoea of \<14 days presenting at the paediatric emergency and outpatient clinic\
Exclusion criteria: refusal of consent, malnutrition, medical condition requiring hospitalization, received anti‐diarrhoea medication or antibioticsInterventions3 RDA zinc sulphate in a syrup once daily (15 mg zinc for 6 to 12 months children and 30 mg for 12 to 60 months) for 14 days + ORS.ORS.OutcomesDuration of diarrhoea.Adverse events (vomiting).NotesWe requested additional information from the trial author, but did not receive any reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used block randomization with 8 numbers in each block.Allocation concealment (selection bias)Unclear riskThe trial did not mention these details.Blinding (performance bias and detection bias)   All outcomesHigh riskThere was no blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskFifteen participants (5.36%) were lost to follow‐upSelective reporting (reporting bias)Unclear riskThe trial authors did not include the RCT protocol registration number.Other biasUnclear riskThere was no further information available on other sources of bias.[Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}MethodsRCTParticipantsN: 275 participants\
Inclusion criteria: male, 1 to 6 months; onset \< 72 hours; some dehydration or \> 100 mL of watery stool within a 4‐hour observation period\
Exclusion criteria: clinical signs of zinc deficiency; kwashiorkor, weight/age \< 60% NCHS; grossly bloody stool comorbidity; choleraInterventionsZinc acetate: 20 mg.Zinc acetate: 5 mg.Placebo.OutcomesDeath.Average duration of diarrhoea.Stool output.Stool frequency.Adverse events (vomiting).NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a random numbers table to randomize participants to treatment.Allocation concealment (selection bias)Unclear riskThe trial used bottles labelled with randomization numbers; but did not provide any other details.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk5% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no information available on other sources of bias.[Brooks 2005a (20 mg)](#CD005436-bbs2-0007){ref-type="ref-list"}MethodsSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}ParticipantsN: 91 participants (5% lost to follow‐up)InterventionsZinc acetate: 20 mg.Placebo.OutcomesSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}NotesSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Allocation concealment (selection bias)Unclear riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Incomplete outcome data (attrition bias)   All outcomesLow risk5% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Other biasUnclear riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.[Brooks 2005a (5 mg)](#CD005436-bbs2-0008){ref-type="ref-list"}MethodsSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}ParticipantsN: 91 participants (7% lost to follow‐up)InterventionsZinc acetate: 5 mg.Placebo.OutcomesSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}NotesSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"}***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Allocation concealment (selection bias)Unclear riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Incomplete outcome data (attrition bias)   All outcomesLow risk7% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.Other biasUnclear riskSee [Brooks 2005a](#CD005436-bbs2-0006){ref-type="ref-list"} for all descriptions.[Crisinel 2015](#CD005436-bbs2-0009){ref-type="ref-list"}MethodsRCTParticipantsN = 148 participants\
Inclusion criteria: children 2 months to 5 years of age, acute diarrhoea (3 or more stools a day for \< 72 hours) at emergency department\
Exclusion criteria: severe malnutrition (−3 standard deviations (SDs)), ongoing zinc treatment, overwhelming chronic medical condition, non‐French speaking parents, hypersensitivity to component of zinc or placebo, phenylketonuriaInterventionsZinc tablets of 10 mg (children \< 6 months) or 20 mg (children ≥ 6 months) once a day for 10 days plus ORS.Placebo plus ORS.OutcomesDiarrhoea at day 3 and day 5.Adverse events (vomiting, difficulties in treatment administration).NotesResults recorded as medians with IQR because data was not normally distributed.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskWHO performed block randomization.Allocation concealment (selection bias)Low riskAn institutional pharmacy assigned a study number to each package of zinc or placebo.Blinding (performance bias and detection bias)   All outcomesLow riskThe same packaging and dosage were used for the intervention and control groups.Incomplete outcome data (attrition bias)   All outcomesHigh riskOver 40% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThis RCT was not registered.Other biasUnclear riskNo information.[Dalgic 2011](#CD005436-bbs2-0010){ref-type="ref-list"}MethodsRCTParticipantsN: 120 participants\
Inclusion criteria: 1 to 28 months and, on admission, stool positive for rotavirus antigen.  \
Exclusion criteria: severe malnutrition (weight for height \< −3SD as for WHO standards): duration of diarrhoea \> 96 hours; severe dehydration; exclusively breast‐feeding; toxic clinical appearance; immunosuppression; any known allergies to any drugs or foods.InterventionsZinc 20 mg/day.Placebo.OutcomesAverage duration of diarrhoea.Hospitalization.NotesLocation: Turkey\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated.Allocation concealment (selection bias)Unclear riskAllocation concealment was not specified.Blinding (performance bias and detection bias)   All outcomesUnclear riskThe trial authors stated the trial was \"single blind\", but did not provide further details.Incomplete outcome data (attrition bias)   All outcomesLow riskAll children completed the study.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available.[Dutta 2000](#CD005436-bbs2-0011){ref-type="ref-list"}MethodsRCTParticipantsN: 80 participants\
Inclusion criteria: male, 3 to 24 months; malnourished (\< 80% Harvard Standard weight for age); clinical signs of dehydration\
Exclusion criteria: antibiotics; systemic infections; chronic diseases; need for intensive care; exclusively breastfedInterventionsZinc sulphate: 40 mg/day.Placebo.OutcomesAverage duration of diarrhoea.Diarrhoea at day 5.Stool output.NotesLocation: India\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskThe trial kept code numbers in a sealed envelope; zinc and placebo bottles were identical.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesUnclear riskThe trial did not specify the number of participants lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available on other sources of bias.[Dutta 2011](#CD005436-bbs2-0012){ref-type="ref-list"}MethodsRCTParticipantsN: 84 participants\
Inclusion criteria: age 6 to 24 months, history of acute watery diarrhoea, moderate dehydration\
Exclusion criteria: severe malnutrition (weight on height \< −3SD WHO reference); systemic illness; chronic underlying disease (for example, tuberculosis, liver diseases) or needing intensive care; exclusively breastfed; antibiotics before enrolment or vitamin A within the previous 6 monthsInterventionsZinc 20 mg/day.Placebo.OutcomesAverage duration of diarrhoea.Diarrhoea at day 5.Stool output.NotesLocation: India\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskThe trial kept code numbers in a sealed envelope; zinc and placebo bottles were identical.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskThe number of participants lost to follow‐up was \< 10%.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available on sources of bias.[Fajolu 2008](#CD005436-bbs2-0013){ref-type="ref-list"}MethodsRCTParticipantsN: 60 participants\
Inclusion criteria: age 6 to 24 months; acute diarrhoea (less than 14 days duration)\
Exclusion criteria: refusal of consent; protein energy malnutrition; use of stool hardeners, antimotility drugs ant antibiotics; other medical condition requiring hospitalizationInterventionsZinc sulphate 20 mg (\>12 months) or 10 mg (\< 12 months).Placebo.OutcomesAverage duration of diarrhoea.Stool frequency.NotesLocation: Nigeria\
Setting: hospital (follow‐up in the community)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not provide these details.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide these details.Blinding (performance bias and detection bias)   All outcomesUnclear riskThe trial authors did not provide these details.Incomplete outcome data (attrition bias)   All outcomesUnclear riskThe trial authors did not specify the number of participants lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available on other sources of bias.[Faruque 1999](#CD005436-bbs2-0014){ref-type="ref-list"}MethodsRCTParticipantsN: 684 participants\
Inclusion criteria: children 6 to 24 months with acute diarrhoea, some dehydration and no severe dehydration; underweight or stunted children were not excluded\
Exclusion criteria: marasmus; kwashiorkor; systemic illnessesInterventionsZinc acetate: 14.2 mg (first 417 children) or 40 mg (other 273 children randomized).Placebo.\
Both groups: vitamin AOutcomesAverage duration of diarrhoea.Diarrhoea at day 7.NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskThe trial used bottles serially numbered according to the randomization schedule to correspond to the serial number of the participant; a pharmaceutical company prepared the supplements and provided them in dark‐coloured bottles.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk4% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no information available on other sources of bias.[Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}MethodsRCTParticipantsN: 1110 participants\
Inclusion criteria: infants 1 to 5 months of age with acute diarrhoea (\< 72 hours)\
Exclusion criteria: severe malnutrition (\< −3 z score weight for age); signs of pneumonia if \< 2 months (cough and difficult or fast breathing with a respiratory rate of \> 60 breaths/minute); signs severe pneumonia if 2 to 5 months of age (cough or difficult fast breathing and chest indrawing, nasal flaring, or grunting); required hospitalization (overnight stay at a healthcare facility) for any reason; known major congenital malformation; any other serious pre‐existing medical condition; lived out of or planned to move out of study area within following 3 months; previously enrolled in the studyInterventionsZinc sulphate: 10 mg.Placebo.OutcomesDeath.Average duration of diarrhoea.Diarrhoea at day 7.Stool frequency.Hospitalization.Adverse events (vomiting).NotesLocation: Ethiopia, India, and Pakistan\
Setting: community***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskThe trial assigned the randomization scheme in Geneva and kept it secure until completion of data collection and initial analysis; upon enrolment, infants were assigned chronological study identifiers corresponding to a prelabelled blister pack of either zinc or placebo tablets.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk3% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available on other sources of bias.[Fischer Walker 2006 ETH](#CD005436-bbs2-0016){ref-type="ref-list"}MethodsSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}ParticipantsN: 177 participants (8% lost at follow‐up)InterventionsSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}OutcomesSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}NotesLocation: Ethiopia***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow risk8% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Other biasUnclear riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.[Fischer Walker 2006 IND](#CD005436-bbs2-0017){ref-type="ref-list"}MethodsSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}ParticipantsN: 373 participants (1% lost to follow‐up)InterventionsSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}OutcomesSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}NotesLocation: India***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow risk1% participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Other biasUnclear riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.[Fischer Walker 2006 PAK](#CD005436-bbs2-0018){ref-type="ref-list"}MethodsSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}ParticipantsN: 560 participants (3% lost to follow‐up)InterventionsSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}OutcomesSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}NotesLocation: Pakistan***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow risk3% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.Other biasUnclear riskSee [Fischer Walker 2006](#CD005436-bbs2-0015){ref-type="ref-list"}.[Jiang 2016](#CD005436-bbs2-0019){ref-type="ref-list"}MethodsRCTParticipantsN: 103 participants\
Inclusion criteria: children diagnosed with acute diarrhoea,duration within 48 hours, age 3 months to 3 years, rotavirus enteritis (colloidal gold method should be used to detect RV antigen expression) and informed consent\
Exclusion criteria: mucous and bloody stool, stool routine shows white blood cells \> 5 /high power field or red blood cells \> 5 /high power field, total white blood cells \> 12 × 10^9^/L, C reactive protein \> 10 mg/L, children with some underlying diseases such as congenital heart disease, hepatopathy and epilepsyInterventionsZinc gluconate granules (10mg) in children 3 to 6 months, and 20 mg in children over 6 months.Microecologic products with some extra treatments for myocardial nutrients, protect liver, relieve cough, reduce phlegm, and improve microcirculation (vitamin C) for children with abnormal laboratory indexes.OutcomesDuration of diarrhoea.Diarrhoea at day 3.NotesNone***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not mention how allocation sequence was generated.Allocation concealment (selection bias)Unclear riskThe trial authors did not mention how allocation concealment was conducted.Blinding (performance bias and detection bias)   All outcomesUnclear riskThe trial authors did not mention how blinding was achieved for participants, intervention providers, and assessors.Incomplete outcome data (attrition bias)   All outcomesLow riskThere was no loss to follow‐up of participants.Selective reporting (reporting bias)Unclear riskThere was no number of protocol registration.Other biasUnclear riskThe trial was not registered.[Jin 2013](#CD005436-bbs2-0020){ref-type="ref-list"}MethodsRCTParticipantsN: 103 participants\
Inclusion criteria: 4 to 40 months of age; infants with acute rotavirus diarrhoea; parental consent\
Exclusion criteria: not reportedInterventionsZinc gluconate (20 mg of zinc/day).Montmorillonite.OutcomesDiarrhoea at day 3.Average number of hospitalization (days).NotesWe requested additional information from the trial author, but received no reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was no mention of how random sequence was generated.Allocation concealment (selection bias)Unclear riskThere was no mention of how allocation concealment was performed.Blinding (performance bias and detection bias)   All outcomesUnclear riskIt was unclear whether or not blinding was done.Incomplete outcome data (attrition bias)   All outcomesLow riskThere was no loss of participants to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no RCT protocol registration number.Other biasUnclear riskThere was no information available on other sources of bias.[Karamyyar 2013](#CD005436-bbs2-0021){ref-type="ref-list"}MethodsRCTParticipantsN: 379 participants\
Inclusion criteria: children aged 9 months to 5 years, admission to hospital with acute watery diarrhoea and moderate dehydration\
Exclusion criteria: chronic diseases (cystic fibrosis, inflammatory bowel disease, malabsorption), severe malnutrition (weight curve under 3% for age), dysentery and bloody diarrhoea with red blood cells (RBCs) or white blood cells (WBCs) in stool, recent consumption of antibiotics, severe dehydration, persistent vomiting, consumption of zinc supplements (in the last month), drug intolerance, refusal to consentInterventionsZinc supplementation (syrup 1ml/kg/day with 1 mg zinc sulphate divided into two doses) + ORS.ORS.OutcomesStool frequency.NotesWe requested additional information from the trial author, but received no reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computer‐generated allocation sequence.Allocation concealment (selection bias)Low riskA randomization list (simple randomly allocation of two group) was given to the pharmacist prior to enrolment. Randomization codes were secured until the completion of data collection and neither the physician, participants (or their parents), nor nurse were unaware of the drug or placebo.Blinding (performance bias and detection bias)   All outcomesLow riskThe glass bottles that contained the products (zinc Sulfate or placebo) were labelled with participants' code (with keeping the names of participants) by pharmacists who was not involved in the treatments. A placebo with similar taste, colour, and smell and with a similar option (1 mL/kg/day) was given to the control group.Incomplete outcome data (attrition bias)   All outcomesHigh risk15.5% of participants were lost to follow‐up (\> 10%).Selective reporting (reporting bias)Low riskThe outcomes were reported according to the protocol. The RCT was registered (IRCT201201241580N2).Other biasUnclear riskThere was no information available on other sources of bias.[Khatun 2001](#CD005436-bbs2-0022){ref-type="ref-list"}MethodsRCTParticipantsN: 100 participants\
Inclusion criteria: 6 to 36 months; moderately malnourished (61% to 75% of the median NCHS median weight for age); persistent diarrhoea\
Exclusion criteria: systemic infection; clinical signs of vitamin A deficiency; received vitamin A supplementation within 3 months; received prior antibiotics therapy; bloody mucoid diarrhoea; kwashiorkor; no longer received breast milkInterventionsZinc acetate: 20 mg.Placebo.\
Both groups: multivitaminsOutcomesDeath.Average duration of diarrhoea.Diarrhoea at day 7.Stool output.Adverse events (vomiting).NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not provide these details.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide these details.Blinding (performance bias and detection bias)   All outcomesUnclear riskThe trial authors did not provide these details.Incomplete outcome data (attrition bias)   All outcomesLow risk4% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no further information available on other sources of bias.[Larson 2005](#CD005436-bbs2-0023){ref-type="ref-list"}MethodsRCTParticipantsN: 1067 participants\
Inclusion criteria: children aged 3 to 59 months; acute diarrhoea; having taken ORS as instructed; no vomiting in the past 2 hours for the short‐stay ward or 30 minutes in the outpatient clinic, and no longer dehydrated\
Exclusion criteria: returning to the hospital with diarrhoea; receiving zincInterventionsZinc sulphate: 20 mg.Placebo.OutcomesAdverse events (vomiting).NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskThe trial used opaque envelopes, numbered, in which the assigned zinc tablet, placebo tablet, or a similar‐sized button was placed; and kept the randomization schedule in a locked cabinet.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskNo participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskThere was no information available on other sources of bias.[Passariello 2015](#CD005436-bbs2-0024){ref-type="ref-list"}MethodsRCTParticipantsN: 83 participants\
Inclusion criteria: children aged between 5 to 36 months, diarrhoea lasting less than 24 hours with mild‐moderate dehydration\
Exclusion criteria: malnutrition ( weight/height ratio) \< 5^th^ percentile), severe dehydration, concomitant severe or chronic systemic illness, immunodeficiency, cystic fibrosis, food allergy, chronic gastrointestinal disease, endocrine disease, use of pre/pro/symbiotic antibiotics, any anti‐diarrhoea medication in the previous 3 weeksInterventionsHypotonic super ORS containing zinc in a gel formulation.Standard hypotonic ORS.OutcomesDuration of diarrhoea.Diarrhoea on day 3.Adverse events (vomiting).NotesWe requested additional information from the trial authors, but received no reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computer‐generated randomization to assign participants to treatment.Allocation concealment (selection bias)Low riskThe hospital pharmacy produced identical white aluminium fold sachets contained in a blank blinded code‐labelled paper box for intervention and controls.Blinding (performance bias and detection bias)   All outcomesUnclear riskWe requested additional information from the trial authors, but received no reply.Incomplete outcome data (attrition bias)   All outcomesLow riskThere was no loss of participants to follow‐up.Selective reporting (reporting bias)Unclear riskThe RCT was registered retrospectively (ACTRN12614000028606).Other biasUnclear riskThere was no further information available on other sources of bias.[Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}MethodsRCTParticipantsN: 808 participants\
Inclusion criteria: age 6 to 59 months; acute diarrhoea (duration up to 72 hours); ability to accept oral fluids or feeds  \
Exclusion criteria: severe dehydration and unable to drink, chronic or severe complicating illness, known positive HIV status, kwashiorkor, residing outside a radius of 30 km around the hospital, participating in another study or already enrolled in this studyInterventionsZinc sulcates 2 mg/kg/day.Zinc sulphate 2 mg/kg/day + copper 0.2 mg/kg/day.Placebo.OutcomesDeath.Average duration of diarrhoea.Diarrhoea at day 3.Diarrhoea at day 5.Diarrhoea at day 7.NotesLocation: India\
Setting: hospital (follow‐up in the community)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSingle‐site, blocked randomization procedure with blocks of sizes 3, 6, and 9 in equal proportions.Allocation concealment (selection bias)Low riskRandomization list generated off site by an investigator not directly involved in the data collection. The code list of the placebo and the treatment groups was secured and held only by the pharmacist at the Universal Medicaments Pvt. Ltd, Nagpur, until initial data analysis was completed.Blinding (performance bias and detection bias)   All outcomesLow riskDouble blind: bottle packs sequentially labelled according to the treatment allocation list and assigned to participants by the research physician.Incomplete outcome data (attrition bias)   All outcomesLow risk7% lost at follow‐up.Selective reporting (reporting bias)Low riskThe protocol was available. The trial was registered in the *meta*Register of Controlled Trials (ISRCTN85071383).Other biasUnclear riskThere was no information available on other sources of bias.[Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}MethodsRCTParticipantsN: 808 participants\
Inclusion criteria: age 6 to 59 months; acute diarrhoea (duration up to 72 hours); ability to accept oral fluids or feeds  \
Exclusion criteria: severe dehydration and unable to drink,chronic or severe complicating illness, known positive HIV status, kwashiorkor, residing outside a radius of 30 km around the hospital, participating in another study or already enrolled in this studyInterventionsZinc sulphate 2 mg/kg/die.Zinc sulphate 2 mg/kg/die + copper 0.2 mg/kg/die.Placebo.OutcomesDeath.Average duration of diarrhoea.Diarrhoea at day 3.Diarrhoea at day 5.Diarrhoea at day 7.NotesLocation: India\
Setting: hospital (follow‐up in the community)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Selective reporting (reporting bias)Low riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Other biasUnclear riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.[Patel 2009b (zinc + copper)](#CD005436-bbs2-0027){ref-type="ref-list"}MethodsSee [Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}ParticipantsSee [Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}InterventionsSee [Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}OutcomesSee [Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}NotesSee [Patel 2009a (zinc)](#CD005436-bbs2-0026){ref-type="ref-list"}***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Selective reporting (reporting bias)Low riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.Other biasUnclear riskSee [Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}.[Patel 2015](#CD005436-bbs2-0028){ref-type="ref-list"}MethodsRCTParticipantsN: 100 participants\
Inclusion criteria: children \< 12 years (but all enrolled had ≤ 5 years), presentation to hospital with diarrhoea\
Exclusion criteria: serious illness, intensive care admission, use of ventilators, impossibility of communicationInterventionsOral zinc sulphate (10 mg for \< 6 months a day or 20 mg for ≥ 6 months) per 14 days + standard of care (ORS, intravenous fluid, antibiotics).Standard of care (ORS, intravenous fluid, antibiotics).OutcomesDiarrhoea at day 3 and 5.NotesWe requested additional information from the trial authors, but received no reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom sequence generation was computer generated.Allocation concealment (selection bias)Unclear riskThe trial authors did not clearly describe allocation concealment.Blinding (performance bias and detection bias)   All outcomesHigh riskThis was an open label trial.Incomplete outcome data (attrition bias)   All outcomesLow risk4% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no RCT registration number.Other biasUnclear riskThere was no information on other sources of bias.[Patro 2010](#CD005436-bbs2-0029){ref-type="ref-list"}MethodsRCTParticipantsN: 160 participants\
Inclusion criteria: age 3 to 48 months diagnosed with acute diarrhoea lasting less than 5 days, with at least some degree of dehydration\
Exclusion criteria: diarrhoea lasting \<1 day or \>5 days, recent history of diarrhoea (last 2 weeks before enrolment day), chronic gastrointestinal disease with diarrhoea manifestation, (for example, food allergy, coeliac disease), weight‐to‐height ratio \< 5^th^ percentile, severe dehydration, coexistence of serious systemic disease(s), coadministration of antibiotics, exclusive or \> 50% breastfeeding, immunodeficiency, immunosuppressive therapy.InterventionsZinc sulphate (20 mg in children \> 6 months or 10 mg in children \< 6 months).Placebo.OutcomesAverage duration of diarrhoea.Diarrhoea at day 7.NotesLocation: Poland\
Setting: hospital (90% of children) and outpatient (10%)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskAn investigator at the Medical University of Warsaw computer‐generated 2 different randomization lists for each centre.  Allocation concealment (selection bias)Low riskThe glass bottles containing the products were labelled with the participant's number corresponding to the randomization list by an independent individual who was not involved in participant enrolment. Randomization codes were secured until the completion of data collection and initial analysis. The placebo was identically supplied and formulated. There was no difference between zinc and the placebo in appearance; a minor metallic aftertaste of zinc was hardly detectable.Blinding (performance bias and detection bias)   All outcomesLow riskInvestigators, participants, outcome assessors, and data analysts were blinded.Incomplete outcome data (attrition bias)   All outcomesHigh risk11.8% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no protocol available.Other biasUnclear riskNote: the source of funding was Nutricia.[Penny 1999](#CD005436-bbs2-0030){ref-type="ref-list"}MethodsRCTParticipantsNumber: 413\
Inclusion criteria: 6 to 36 months, persistent diarrhoea\
Exclusion criteria: vitamins or minerals within 6 weeks; major congenital malformation affecting growth; severe dehydration; requiring hospitalizationInterventionsZinc gluconate: 20 mg.Placebo.OutcomesDeath.Hospitalization.Diarrhoea at day 3.Diarrhoea at day 5.Diarrhoea at day 7.Adverse events (vomiting).NotesLocation: Peru\
Setting: community***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computer‐generated random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskRandomization numbers were linked to letter codes, each indicating 1 treatment group; codes were kept secret; independent laboratories provided supplements.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskNo participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available on other sources of bias.[Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}MethodsRCTParticipantsN: 200 participants\
Inclusion criteria: 2 to 29 months; malnourished children (weight for age scale, score \< 76% according to NCHS standards); acute non‐bacterial diarrhoea\
Exclusion criteria: concomitant illness or oedemaInterventionsZinc sulphate: 20 mg.Placebo.OutcomesAverage duration of diarrhoea.Diarrhoea at day 3.Diarrhoea at day 7.Adverse events (vomiting).NotesLocation: Turkey\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskBottles were labelled with randomization numbers.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk9% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available on other sources of bias.[Polat 2003 (low Zn)](#CD005436-bbs2-0032){ref-type="ref-list"}MethodsSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}ParticipantsN: 76 participants\
Children with low zinc serum levelsInterventionsSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}OutcomesSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}NotesSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Selective reporting (reporting bias)Unclear riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Other biasUnclear riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.[Polat 2003 (normal Zn)](#CD005436-bbs2-0033){ref-type="ref-list"}MethodsSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}ParticipantsN: 106 participants\
Children with normal zinc serum levelsInterventionsSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}OutcomesSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}NotesSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Allocation concealment (selection bias)Low riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Blinding (performance bias and detection bias)   All outcomesLow riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Incomplete outcome data (attrition bias)   All outcomesLow riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Selective reporting (reporting bias)Unclear riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.Other biasUnclear riskSee [Polat 2003](#CD005436-bbs2-0031){ref-type="ref-list"}.[Roy 1997](#CD005436-bbs2-0034){ref-type="ref-list"}MethodsRCTParticipantsN: 111 participants  Inclusion criteria: 2 to 24 months; weight below the 76^th^ centile of weight‐for‐age according to the NCHS standard 18 (by Gomez classification, protein energy malnutrition grades II and III included)\
Exclusion criteria: systemic infection or oedemaInterventionsZinc acetate: 20 mg.Placebo.\
Both groups: multivitaminOutcomesAverage duration of diarrhoea.Stool output.NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a table of random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskBottles were labelled with randomization numbers.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesHigh risk32.4% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskNo protocol was availableOther biasUnclear riskNo information was available on other sources of bias.[Roy 1998](#CD005436-bbs2-0035){ref-type="ref-list"}MethodsRCTParticipantsN: 190 participants\
Inclusion criteria: 3 to 24 months; persistent diarrhoea; underweight (low weight‐for‐age) using a cut‐off of 70% weight/age of the 50th centile of the NCHS standard; wasted (low weight/height) using a cut‐off of 80%; short (low height/age) using a cut‐off of less than 95% of the height/age standard\
Exclusion criteria: none statedInterventionsZinc acetate: 20 mg.Placebo.\
Both groups: multivitaminOutcomesDeath.Average duration of diarrhoea.Adverse events.NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Unclear riskThe trial did not provide any details on allocation concealment.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesUnclear riskIt was unclear whether or not any participants were lost to follow‐up; 11% discontinued the intervention.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available on other sources of bias.[Roy 2008a](#CD005436-bbs2-0036){ref-type="ref-list"}MethodsRCTParticipantsN: 56 participants\
Inclusion criteria: aged 12 to 59 months; moderately malnourished (weight/age 61% to 75% of NCHS median); history suggestive of dysentery (for example, bloody‐mucoid diarrhoea or febrile diarrhoea less than 5 days\' duration); with culture‐proven shigellosis\
Exclusion criteria: severe malnutrition; receiving zinc supplementation; measles in the last 6 months; living beyond 2 hours of travel time; complications such as haemolytic uraemic syndrome or other systemic illness, including pneumonia, meningitis, and septicaemiaInterventionsZinc acetate: 10 mg.Placebo.\
Both groups: multivitaminsOutcomesDeath.Average duration of diarrhoea.Diarrhoea at day 7.NotesLocation: Bangladesh\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a table of random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskBottles were identical and labelled with sequential numbers that had earlier been allocated to either intervention or control according to the randomization.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesHigh risk11% of participants were lost to follow‐up.Selective reporting (reporting bias)Low riskThe trial was registered at ClinicalTrials.gov (NCT00321126).Other biasUnclear riskNo information was available on other sources of bias.[Sachdev 1988](#CD005436-bbs2-0037){ref-type="ref-list"}MethodsRCTParticipantsN: 50 participants\
Inclusion criteria: children 6 to 18 months; dehydration secondary to acute diarrhoea of \< 4 days\' duration\
Exclusion criteria: antibiotics; severe malnutrition (grades III and IV); concomitant features (meningitis, pneumonia, liver disease, otitis media, fever \> 39°C)InterventionsZinc sulphate: 20 mg.Placebo.OutcomesAverage duration of diarrhoea.Stool frequency.Adverse events (vomiting).NotesLocation: India\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not provide any details.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any details.Blinding (performance bias and detection bias)   All outcomesUnclear riskThe trial authors did not provide any details.Incomplete outcome data (attrition bias)   All outcomesUnclear riskThe trial authors did not provide any details.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available.[Sachdev 1990](#CD005436-bbs2-0038){ref-type="ref-list"}MethodsRCTParticipantsN: 40 participants\
Inclusion criteria: 6 to 18 months; persistent diarrhoea\
Exclusion criteria: another diarrhoeal episode 1 month prior; critically ill; obvious parenteral infections; severe malnutrition (grade III and IV)InterventionsZinc sulphate: 20 mg.Placebo.OutcomesAverage duration of diarrhoea.Stool frequency.Adverse events (vomiting).NotesLocation: India\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not provide any details.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any details.Blinding (performance bias and detection bias)   All outcomesUnclear riskThe trial authors did not provide any details.Incomplete outcome data (attrition bias)   All outcomesUnclear riskThe trial authors did not provide any details.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available on other sources of bias.[Sazawal 1995](#CD005436-bbs2-0039){ref-type="ref-list"}MethodsRCTParticipantsN: 947 participants\
Inclusion criteria: 6 to 35 months; diarrhoea for 7 days; permanent resident in study area; stunted defined (length for age less than −2 SD)\
Exclusion criteria: second visit; malnutrition requiring hospitalization; not provide consentInterventionsZinc gluconate: 20 mg.Placebo.\
Both groups: multivitaminOutcomesDiarrhoea at day 7.Stool frequency.Adverse events (vomiting).NotesLocation: India\
Setting: hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskChildren were allocated to sequential numbers indicating zinc or placebo; the WHO kept the code, which was not available to the trial investigators.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk2% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available.[Shimelis 2008](#CD005436-bbs2-0040){ref-type="ref-list"}MethodsRCTParticipantsN: 414 participants\
Inclusion criteria: children 2 to 59 months, presented at the hospital with acute watery diarrhoea for less than 7 days\
Exclusion criteria:children living far or unsafe areas for follow‐up, children requiring antimicrobial for other conditions, immunocompromised (severely malnourished or with known primary immune deficiency) excluding cases of measles or those with HIV positive status, special fluid requirements (that is, renal disease, health hepatic failure), chronic or persistent diarrhoea and dysentery requiring hospitalization or admitted for in‐patient care, on zinc supplementation, no consentInterventionsZinc (2 tablets each containing 10 mg zinc) and ORS.ORS.OutcomesDiarrhoea at day 5.Adverse events: vomiting.NotesWe requested additional information from the trial author, but received no reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskThe trial used randomly selected days to assign participants to treatment.Allocation concealment (selection bias)High riskThere was no randomization concealment since participants were randomized depending on the day they reported to the health facility.Blinding (performance bias and detection bias)   All outcomesHigh riskThis was an open label trial.Incomplete outcome data (attrition bias)   All outcomesLow risk3% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThere was no RCT registration number. We requested additional information from the trial authors but received no reply.Other biasUnclear riskThere was no information available on other sources of bias.[Strand 2002](#CD005436-bbs2-0041){ref-type="ref-list"}MethodsRCTParticipantsN: 899 participants\
Inclusion criteria: 6 to 35 months; diarrhoea \< 96 hours\
Exclusion criteria: massive dose of vitamin A; requiring hospitalization; family intended to leave Bhaktapur within 2 monthsInterventionsZinc gluconate: 15 mg for infants; 30 mg for older children.Placebo.OutcomesDiarrhoea at day 3.Diarrhoea at day 7.Adverse events (vomiting).Adverse events (copper levels).NotesLocation: Nepal\
Setting: community***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used random numbers to assign participants to treatment.Allocation concealment (selection bias)Low riskPacking with serial number; the list was kept in Copenhagen; capsules were identical in appearance; the syrup was identical in appearance and taste.Blinding (performance bias and detection bias)   All outcomesLow riskThe trial was double blinded.Incomplete outcome data (attrition bias)   All outcomesLow risk1% of participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskNo protocol was available.Other biasUnclear riskNo information was available.[Tran 2015](#CD005436-bbs2-0042){ref-type="ref-list"}MethodsRCTParticipantsN: 76 participants\
Inclusion criteria: children 6 months to 12 years,clinically diagnosed with diarrhoea and tolerate oral feed\
Exclusion criteria: other gastrointestinal symptoms, history of gastrointestinal surgery with organic disease (excluding previous gastrostomy, pyloric stenosis), phenylketonuric or diabetic, taking gastric acid‐neutralizing antacids, drugs to suppress gastric acid secretion or anti‐diarrhoeal drugs, probiotics or zinc supplement, immunocompromised, proven sucrose intolerance, or previously participated in the studyInterventionsORS (Gastrolyte‐R sachets) with zinc sulphate fortification (3 mg elemental zinc in total) to be mixed with 200 mL water for 4 days up to a maximum of 4 sachets in 24 hours).ORS (Gastrolyte‐R sachets).OutcomesDuration of diarrhoea.NotesWe requested additional information from the trial author, but received no reply***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated random sequence.Allocation concealment (selection bias)Unclear riskNot clearly described.Blinding (performance bias and detection bias)   All outcomesLow riskAll bottles packaged by the manufacturing pharmacy.Incomplete outcome data (attrition bias)   All outcomesHigh riskLost to follow‐up in both study arms = 23.7% (\> 10%).Selective reporting (reporting bias)Unclear riskNo RCT registration number. We did not receive a response from the trial authors.Other biasUnclear riskNo information available.[^1]

Characteristics of excluded studies \[ordered by study ID\] {#CD005436-sec-0134}
===========================================================

StudyReason for exclusion[Abraham 2016](#CD005436-bbs2-0043){ref-type="ref-list"}This study did not concern the intervention of interest to this review[Adu‐Afarwuah 2007](#CD005436-bbs2-0044){ref-type="ref-list"}This study did not concern the intervention of interest (3 types of micronutrients for food fortification)[Adu‐Afarwuah 2008](#CD005436-bbs2-0045){ref-type="ref-list"}This study did not concern the intervention of interest (zinc fortification)[Aggarwal 2007](#CD005436-bbs2-0046){ref-type="ref-list"}Randomized controlled trial (RCT) on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Agustina 2007](#CD005436-bbs2-0047){ref-type="ref-list"}This study did not concern the intervention of interest (probiotic, prebiotic, fibre, and micronutrient mixture)[Alam 2010](#CD005436-bbs2-0048){ref-type="ref-list"}Prevention study[Alarcon 2004](#CD005436-bbs2-0049){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Awasthi 2006](#CD005436-bbs2-0050){ref-type="ref-list"}This study did not concern the intervention of interest (zinc in oral rehydration solution (ORS))[Baqui 2002](#CD005436-bbs2-0051){ref-type="ref-list"}A community RCT without a placebo group[Baqui 2003](#CD005436-bbs2-0052){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Baqui 2006](#CD005436-bbs2-0053){ref-type="ref-list"}This study did not concern any outcome of interest (serum zinc) to this review[Baum 2010](#CD005436-bbs2-0054){ref-type="ref-list"}This study did not concern the population of interest (adults, HIV‐positive)[Becquey 2016](#CD005436-bbs2-0055){ref-type="ref-list"}This study did not concern the intervention of interest to this review[Behrens 1990](#CD005436-bbs2-0056){ref-type="ref-list"}This study did not concern any outcome of interest (nutritional status)[Bhandari 2002](#CD005436-bbs2-0057){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Bhandari 2005](#CD005436-bbs2-0058){ref-type="ref-list"}This was not a RCT[Bhandari 2007](#CD005436-bbs2-0059){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Bhandari 2008](#CD005436-bbs2-0060){ref-type="ref-list"}A RCT without a placebo group[Bhatnagar 2004b](#CD005436-bbs2-0061){ref-type="ref-list"}This was not a RCT[Bhutta 2000a](#CD005436-bbs2-0062){ref-type="ref-list"}This study did not concern any outcome of interest (appetite)[Bilenko 2010](#CD005436-bbs2-0063){ref-type="ref-list"}This study did not concern the intervention of interest (multiple micronutrients in sprinkles)[Black 2001](#CD005436-bbs2-0064){ref-type="ref-list"}Not a RCT[Bobat 2005](#CD005436-bbs2-0065){ref-type="ref-list"}This study did not concern the population of interest (only children with HIV enrolled)[Borges 2007](#CD005436-bbs2-0066){ref-type="ref-list"}This was not a RCT[Brooks 2005b](#CD005436-bbs2-0067){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Brown 2007](#CD005436-bbs2-0068){ref-type="ref-list"}This study did not concern the Intervention of interest (food fortification)[Bruzzese 2016](#CD005436-bbs2-0069){ref-type="ref-list"}This study did not concern the intervention of interest to this review[Chandyo 2010](#CD005436-bbs2-0071){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Chang 2010](#CD005436-bbs2-0072){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Chen 2010](#CD005436-bbs2-0073){ref-type="ref-list"}This study did not concern the intervention of interest (food fortification with multiple micronutrients)[Chhagan 2009](#CD005436-bbs2-0074){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Chhagan 2010](#CD005436-bbs2-0075){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Christian 2009](#CD005436-bbs2-0076){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment, on a different population (pregnant women)[CIGNIS 2010](#CD005436-bbs2-0077){ref-type="ref-list"}This study did not concern the intervention of interest (food fortification with multiple micronutrients)[Colgate 2016](#CD005436-bbs2-0078){ref-type="ref-list"}This study did not concern the intervention of interest to this review[Coronel Carbajal 2000](#CD005436-bbs2-0079){ref-type="ref-list"}This was not a placebo‐controlled RCT[Cross 2009](#CD005436-bbs2-0080){ref-type="ref-list"}Not a RCT[Cárcamo 2006](#CD005436-bbs2-0070){ref-type="ref-list"}This study did not concern the population of interest (adults with HIV)[Dhingra 2009](#CD005436-bbs2-0081){ref-type="ref-list"}Not a RCT[Doherty 1998](#CD005436-bbs2-0082){ref-type="ref-list"}This was not a placebo‐controlled RCT, and the criterion for inclusion of children was malnutrition, not diarrhoea[Ebrahimi 2006](#CD005436-bbs2-0083){ref-type="ref-list"}Thist study did not concern any outcome of interest (growth) to this review[Ellis 2007](#CD005436-bbs2-0084){ref-type="ref-list"}Not a RCT[Ferraz 2007](#CD005436-bbs2-0085){ref-type="ref-list"}Not a RCT[Ferrufino 2007](#CD005436-bbs2-0086){ref-type="ref-list"}Not a RCT[Fischer Walker 2008](#CD005436-bbs2-0087){ref-type="ref-list"}Secondary analysis of a previously excluded study ([Baqui 2002](#CD005436-bbs2-0051){ref-type="ref-list"})[Gardner 2005](#CD005436-bbs2-0088){ref-type="ref-list"}Not a RCT[Garenne 2007](#CD005436-bbs2-0089){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Gebremedhin 2016](#CD005436-bbs2-0090){ref-type="ref-list"}This study did not concern the outcomes of interest to this review[Gregorio 2007](#CD005436-bbs2-0091){ref-type="ref-list"}This study did not concern the intervention of interest (zinc‐fortified ORS)[Gupta 2003](#CD005436-bbs2-0092){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Gupta 2007](#CD005436-bbs2-0093){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Habib 2010](#CD005436-bbs2-0094){ref-type="ref-list"}A longitudinal cohort study[Habib 2013](#CD005436-bbs2-0095){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Heinig 2006](#CD005436-bbs2-0096){ref-type="ref-list"}This study did not concern any outcome of interest (growth, morbidity, and motor development)[Hess 2015](#CD005436-bbs2-0097){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Hettiarachchi 2008](#CD005436-bbs2-0098){ref-type="ref-list"}This study did not concern the population of interest (children 12 to 16 years), nor the outcomes[Hidayat 1998](#CD005436-bbs2-0099){ref-type="ref-list"}A community RCT, but we could not compare the results with other studies because of methodological problems (enrolling the same children more than once) and types of outcomes (episodes of diarrhoea and not children with diarrhoea)[Hoque 2006](#CD005436-bbs2-0100){ref-type="ref-list"}Not a RCT (review)[Hyder 2007](#CD005436-bbs2-0101){ref-type="ref-list"}This study did not concern the population of interest (adolescent girl), the intervention (multiple micronutrients), nor the outcomes[Iannotti 2010](#CD005436-bbs2-0102){ref-type="ref-list"}This study did not concern the population of interest (pregnant women)[Islam 2010](#CD005436-bbs2-0103){ref-type="ref-list"}This study did not concern the population of interest (preterm infants), nor any outcome of interest (growth)[Jimenez 2000](#CD005436-bbs2-0104){ref-type="ref-list"}This study did not concern any outcome of interest (growth)[Kelly 1999](#CD005436-bbs2-0105){ref-type="ref-list"}The intervention and the population (micronutrient supplementation in AIDS diarrhoea‐wasting syndrome) considered in this RCT were not relevant to this review[Kelly 2010](#CD005436-bbs2-0106){ref-type="ref-list"}This study did not concern any outcome of interest (intestinal function) to this review[Kianmehr 2016](#CD005436-bbs2-0107){ref-type="ref-list"}This study did not concern any interventions of interest to this review[Larson 2010](#CD005436-bbs2-0108){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Lin 2008](#CD005436-bbs2-0109){ref-type="ref-list"}This study was not placebo controlled, and did not report outcomes of interest (weight)[Lind 2004](#CD005436-bbs2-0110){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Lind 2008](#CD005436-bbs2-0111){ref-type="ref-list"}A secondary analysis of a previously excluded study ([Lind 2004](#CD005436-bbs2-0110){ref-type="ref-list"})[Lira 1998](#CD005436-bbs2-0112){ref-type="ref-list"}This study did not concern the population of interest (low birthweight infants)[Long 2006](#CD005436-bbs2-0113){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Long 2007](#CD005436-bbs2-0114){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment, with different outcomes (specific intestinal infections)[Lopez 2005](#CD005436-bbs2-0115){ref-type="ref-list"}This study did not concern the intervention of interest (multiple micronutrient), nor the outcomes (anaemia, micronutrient status, growth, and morbidity) of interest to this review[Luabeya 2007](#CD005436-bbs2-0116){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Makonnen 2003a](#CD005436-bbs2-0117){ref-type="ref-list"}This study did not concern any outcome of interest to this review[Makonnen 2003b](#CD005436-bbs2-0118){ref-type="ref-list"}This study did not concern any outcome of interest to this review[Manger 2008](#CD005436-bbs2-0119){ref-type="ref-list"}No placebo control, different intervention (multiple micronutrients), prevention study[Maragkoudaki 2016](#CD005436-bbs2-0120){ref-type="ref-list"}This study did not concern any intervention of interest to this review[Martinez‐Estevez 2016](#CD005436-bbs2-0121){ref-type="ref-list"}This was a prevention study[Mazariegos 2010](#CD005436-bbs2-0122){ref-type="ref-list"}This study did not concern any outcome of interest (linear growth) to this review[Mazumder 2010](#CD005436-bbs2-0123){ref-type="ref-list"}This was a secondary analysis of a previously excluded study ([Bhandari 2008](#CD005436-bbs2-0060){ref-type="ref-list"})[Mda 2010](#CD005436-bbs2-0124){ref-type="ref-list"}This study did not concern a population of interest (only children with HIV), and used a different intervention (multiple micronutrient)[Meeks Gardner 1998](#CD005436-bbs2-0125){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Müller 2001](#CD005436-bbs2-0126){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Naheed 2009](#CD005436-bbs2-0127){ref-type="ref-list"}A secondary analysis of a previously excluded study ([Baqui 2002](#CD005436-bbs2-0051){ref-type="ref-list"})[Nasrin 2005](#CD005436-bbs2-0128){ref-type="ref-list"}Not a RCT[Negi 2014](#CD005436-bbs2-0129){ref-type="ref-list"}The study participants were above 5 years (age range 5 to 12 years)[Nga 2009](#CD005436-bbs2-0130){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Osendarp 2002](#CD005436-bbs2-0131){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Ouedraogo 2008](#CD005436-bbs2-0132){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Passariello 2010](#CD005436-bbs2-0133){ref-type="ref-list"}This study did not concern the intervention of interest (zinc in ORS) to this review[Patel 2005](#CD005436-bbs2-0134){ref-type="ref-list"}This study did not concern the intervention of interest (zinc and copper in ORS)[Patel 2010a](#CD005436-bbs2-0135){ref-type="ref-list"}Secondary analysis of an included study ([Patel 2009](#CD005436-bbs2-0025){ref-type="ref-list"}), with no outcome of interest (by isolated microorganism)[Patel 2010b](#CD005436-bbs2-0136){ref-type="ref-list"}Not a RCT (review)[Patel 2012](#CD005436-bbs2-0137){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Penny 2004a](#CD005436-bbs2-0138){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Penny 2004b](#CD005436-bbs2-0139){ref-type="ref-list"}Not a RCT[Polat 2006](#CD005436-bbs2-0140){ref-type="ref-list"}Not a placebo‐controlled RCT[Prado 2016](#CD005436-bbs2-0141){ref-type="ref-list"}This study used a different intervention that was not of interest to this review[Rahman 2001](#CD005436-bbs2-0142){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Rahman 2005](#CD005436-bbs2-0143){ref-type="ref-list"}This study did not concern any outcome of interest to this review[Raqib 2004](#CD005436-bbs2-0144){ref-type="ref-list"}This study did not concern any outcome of interest (immune and inflammatory responses) to this review[Richard 2006](#CD005436-bbs2-0145){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Rollins 2007](#CD005436-bbs2-0146){ref-type="ref-list"}This study did not concern the population of interest (only HIV‐infected children), and different outcomes (growth, immunity)[Rosado 1997](#CD005436-bbs2-0147){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Rosado 1998](#CD005436-bbs2-0148){ref-type="ref-list"}Not a RCT[Rosado 2009](#CD005436-bbs2-0149){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment, with different outcomes (specific intestinal infections)[Roy 1992](#CD005436-bbs2-0150){ref-type="ref-list"}This study did not concern any outcome of interest (intestinal permeability) to this review[Roy 1999](#CD005436-bbs2-0151){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Roy 2007](#CD005436-bbs2-0152){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Roy 2008b](#CD005436-bbs2-0153){ref-type="ref-list"}This study did not concern the population of interest (children aged between 3 and 14 years)[Ruel 1997](#CD005436-bbs2-0154){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Sabatier 1997](#CD005436-bbs2-0155){ref-type="ref-list"}Not a placebo‐controlled RCT[Samuel 1995](#CD005436-bbs2-0157){ref-type="ref-list"}Not a RCT[Sazawal 1996](#CD005436-bbs2-0158){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Sazawal 1997a](#CD005436-bbs2-0159){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Sazawal 2004](#CD005436-bbs2-0160){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Sazawal 2007a](#CD005436-bbs2-0161){ref-type="ref-list"}This study did not concern the intervention of interest to this review(milk fortification)[Sazawal 2007b](#CD005436-bbs2-0162){ref-type="ref-list"}This study did not concern any outcome of interest to this review (plasma retinol)[Sazawal 2007c](#CD005436-bbs2-0163){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Shamir 2005](#CD005436-bbs2-0164){ref-type="ref-list"}Different intervention (zinc and probiotics)[Shankar 1998](#CD005436-bbs2-0165){ref-type="ref-list"}Not a RCT (review)[Sharieff 2006](#CD005436-bbs2-0166){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Sheikh 2010](#CD005436-bbs2-0167){ref-type="ref-list"}Not a RCT[Sur 2003](#CD005436-bbs2-0168){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Sáenz De Pipaón 2007](#CD005436-bbs2-0156){ref-type="ref-list"}Not a RCT (review)[Taneja 2009](#CD005436-bbs2-0169){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment, in a different population (low birthweight infants)[Taneja 2010](#CD005436-bbs2-0170){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment, with different outcomes (growth)[Tielsch 2006](#CD005436-bbs2-0171){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Tielsch 2007](#CD005436-bbs2-0172){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Umeta 2000](#CD005436-bbs2-0173){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Untoro 2005](#CD005436-bbs2-0174){ref-type="ref-list"}This study did not concern the intervention of interest (multiple micronutrient), nor any outcome of interest to this review (anaemia, micronutrient status, growth, and morbidity)[Valery 2005](#CD005436-bbs2-0175){ref-type="ref-list"}This study did not concern the population of interest (all children aged under 11 years)[Veenemans 2011](#CD005436-bbs2-0176){ref-type="ref-list"}This was a prevention study[Wadhwa 2011](#CD005436-bbs2-0177){ref-type="ref-list"}This was a study on zinc‐enriched ORS[Walden 2004](#CD005436-bbs2-0178){ref-type="ref-list"}Not a RCT[Walker 2007](#CD005436-bbs2-0179){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[Wieringa 2010](#CD005436-bbs2-0180){ref-type="ref-list"}This study did not concern the population of interest to this review (pregnant women)[Winch 2006](#CD005436-bbs2-0181){ref-type="ref-list"}Not a RCT[Winch 2008](#CD005436-bbs2-0182){ref-type="ref-list"}Not a RCT[Wuehler 2008](#CD005436-bbs2-0183){ref-type="ref-list"}A RCT on zinc supplementation for prevention of diarrhoea episodes, not for diarrhoea treatment[^2]

Characteristics of ongoing studies \[ordered by study ID\] {#CD005436-sec-0135}
==========================================================

[NCT01140074](#CD005436-bbs2-0184){ref-type="ref-list"}Trial name or titleEfficacy of zinc sulfate with probiotics for the treatment of acute diarrhoea in childrenMethodsRCTParticipantsInclusion criteria: age 1 to 36 months; a\
cute diarrhoea defined as 3 or more watery stools per day; informed consent (parents)\
Exclusion criteria: severe dehydration (\> 10%); coexisting severe infection (for example, sepsis, pneumonia, meningitis); immune deficiency; chronic digestive tract disease (for example, coeliac disease, food allergy); on antibiotic therapyInterventionsZinc sulphate 10 to 20 mg per day orally plus probiotics.Zinc sulphate 10 to 20 mg per day orally.Placebo.OutcomesPeriod of diarrhoea in hours (time frame: 15 days) (designated as safety issue: no).Number of stools in consequent days (time frame: 15 days).Hospitalization.Tolerability.Adherence to the therapy.Starting dateJuly 2010 (not yet recruiting in December 2010)Contact informationContact: Leszek Szenborn, Prof [szenborn\@zak.am.wroc.pl](szenborn@zak.am.wroc.pl) (principal investigator)\
Contact: Ernest P. Kuchar, MD [kuchar\@zak.am.wroc.pl](kuchar@zak.am.wroc.pl)NotesLocation: Poland\
Registration number: NCT01140074\
Source of funding: unclear\
Sponsor: University Hospital No 1 Wroclaw[NCT01198587](#CD005436-bbs2-0185){ref-type="ref-list"}Trial name or titleA double blind randomized placebo controlled trial of oral zinc for children with acute diarrhoea in a developed nationMethodsRCTParticipantsInclusion criteria\
Healthy children with non‐bloody diarrhoea illness defined as loose or watery stools.Symptoms must be present for greater than 24 hours but less than 72 hours.Comorbid conditions including: asthma, gastroesophageal reflux (unless followed by a gastroenterologist), mild speech, language, motor delays, benign heart murmurs, isolated atrial septal defect (ASD) or ventricular septal defect VSD, epilepsy (unless developmentally delayed), children born prematurely between 33 to 37 weeks without long term sequelae, repaired tetralogy of Fallot (no cardiac issues for \> 6 months), diabetes may be enrolled in the study.\
Exclusion criteria\
Children with symptoms less than 24 hours.Children with symptoms greater than 24 hours.Failure to thrive.G or J tube.Major surgery within last 3 months.Minor surgery (e.g. tonsillectomy, ear tubes, skin lesion removal) within last 1 month.Followed by gastrointestinal service for any reason (Crohn, ulcerative colitis, constipation.Developmental delay, patient \> 1 year behind milestones.Current brain tumour.Currently being treated for cancer or in remission \< 6 months.Intussuception.Antibiotics in the last 14 days or currently taking antibiotics for any reason.Autism.Children born premature \< 33 weeks.Cystic fibrosis.Major congenital heart disease (any disease where child\'s baseline oxygen saturations \< 93%).Short gut.Liver disease.History of bowel resection.\
Age minimum: 6 months  Age maximum: 6 years  Gender: bothInterventionsZinc sulfate:for children aged 6 months to 1 year, 12.5 mg orally daily for 14 days mixed in 60 mL of fluid;for children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid.Placebo.OutcomesDuration of diarrhoea in acute diarrhoeal illnesses in a developed nation while taking zinc or placebo (time frame: 14 days)Starting dateSeptember 2010Contact informationMichelle L Niescierenko, MD\
michelle.niescierenko\@childrens.harvard.edu\
Children\'s Hospital BostonNotesLocation: USA\
Registration number: NCT01198587\
Source of funding: unclear\
Sponsor: Children\'s Hospital Boston[^3]

2016 {#CD005436-sec-0129}
====

We included a PRISMA study flow diagram and funnel plots.

2011 {#CD005436-sec-0130}
====

We used GRADE profiler, version 3.2.2 to create \'Summary of findings' tables for the primary outcomes in the review.

2007, Issue 4 (first review version) {#CD005436-sec-0131}
====================================

We made the following modifications to the review.

We changed the inclusion criteria for participant age to \"children over one month old\" (rather than \"two months\") to avoid arbitrarily losing trials.We amended death to a secondary outcome measure following feedback from referees.We stratified the results by age categories since we observed significant heterogeneity when trials were pooled, and a clear difference in zinc effect was evident according to age.For subgroup analysis by nutritional status, it was not possible to refer to the definition of malnutrition given in the protocol (weight/height) as most included trials used another definition (weight/age), which is easier to measure. The difference between the two definition is that the first identifies children with acute weight loss or \'wasted\', while the second includes both children with acute and chronic malnutrition (\'wasted\' and \'stunted\').Two categories of \'zinc dose\' were used (20 mg and \> 20 mg) as most trials used zinc 20 mg/day, and only two trials used more than 20 mg/day.We added sex (male, female) as a subgroup as it was identified as a possible effect modifier ([Garenne 2005](#CD005436-bbs2-0195){ref-type="ref-list"}).

Both ML and HW contributed equally to the preparation of this Cochrane Review update.
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Department for International Development (DFID), UK.Grant: 5242
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[^1]: Abbreviations: N: number of participants; NCHS: National Center for Health Statistics; ORS: oral rehydration solution; RCT: randomized controlled trial; WHO: World Health Organization.

[^2]: Abbreviations: AIDS: acquired immune deficiency syndrome; HIV: human immunodeficiency virus; ORS: oral rehydration solution; RCT: randomized controlled trial.

[^3]: Abbreviations: MD: medical doctor; RCT: randomized controlled trial.
